<!DOCTYPE html>
<html lang="en" class="no-js">
    <head>
        <title>Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients | Journal of Hematology &amp; Oncology | Full Text</title>

        
    
        
    


        
        
    
    <meta name="journal_id" content='13045'/>
    
    <meta name="dc.title" content='Molecular alterations of isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients'/>
    
    <meta name="dc.description" content='Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to &#945;-ketoglutarate. Acquired somatic mutations of IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases. Two-hundred and thirty newly diagnosed AML patients were analyzed for the presence of IDH1 and IDH2 heterozygous mutations by polymerase chain reaction-denaturing high performance liquid chromatography (PCR-DHPLC) followed by direct sequencing. Clinical and biological characteristics were analyzed and correlated to the IDH mutational status. Coexisting mutations such as FLT3, PML- RARA, RAS, AML1, and NPM1 mutations were additionally explored. The prevalence of IDH1 and IDH2 mutations was 8.7% (20/230) and 10.4% (24/230), respectively. Six missense mutations were identified among IDH1-mutated cases; p.R132H (n = 8), p.R132C (n = 6), p.R132S (n = 2), p.R132G (n = 2), p.R132L (n = 1), and p.I99M (n = 1). Two missense mutations were found in IDH2-mutated cases; p.R140Q (n = 20) and p.R172K (n = 4). No patients had dual IDH1 and IDH2 mutations. About 18% of AML with normal cytogenetics and 31% of acute promyelocytic leukemia had IDH mutations. Half of the IDH-mutated cohort had normal karyotype and the major FAB subtype was AML-M2. Interestingly, IDH1- and IDH2-mutated cases predominantly had NPM1 mutations (60-74%) as compared to the wild type (P &lt; 0.001). Very few IDH-mutated cases had FLT3 and/or RAS abnormalities and none of them had AML1 mutations. Older age and higher median platelet counts were significantly associated with IDH2 mutations although the clinical impact of either IDH1 or IDH2 mutations on patients&#39; overall survival could not be observed. Overall, 19% of newly diagnosed AML patients had alterations of IDH genes. No patients concurrently carried both IDH1 and IDH2 mutations suggesting that these mutations were mutually exclusive. NPM1 mutation appears as a major coexisting genetic mutation in IDH-mutated patients. Our present data failed to support the prognostic relevance of IDH mutations although alterations of these metabolic genes potentially have an important role in leukemia development.'/>
    
    <meta name="dc.source" content='Journal of Hematology &amp; Oncology 2012 5:1'/>
    
    <meta name="dc.format" content='text/html'/>
    
    <meta name="dc.publisher" content='BioMed Central'/>
    
    <meta name="dc.date" content='2012-03-07'/>
    
    <meta name="dc.type" content='OriginalPaper'/>
    
    <meta name="dc.language" content='En'/>
    
    <meta name="dc.copyright" content='2012 Chotirat et al; licensee BioMed Central Ltd.'/>
    
    <meta name="dc.rights" content='http://creativecommons.org/licenses/by/2.0'/>
    
    <meta name="dc.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.issn" content='1756-8722'/>
    
    <meta name="prism.publicationName" content='Journal of Hematology &amp; Oncology'/>
    
    <meta name="prism.publicationDate" content='2012-03-07'/>
    
    <meta name="prism.volume" content='5'/>
    
    <meta name="prism.number" content='1'/>
    
    <meta name="prism.section" content='OriginalPaper'/>
    
    <meta name="prism.startingPage" content='5'/>
    
    <meta name="prism.copyright" content='2012 Chotirat et al; licensee BioMed Central Ltd.'/>
    
    <meta name="prism.rightsAgent" content='reprints@biomedcentral.com'/>
    
    <meta name="prism.url" content='https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-5'/>
    
    <meta name="citation_pdf_url" content='https://jhoonline.biomedcentral.com/track/pdf/10.1186/1756-8722-5-5?site=jhoonline.biomedcentral.com'/>
    
    <meta name="citation_abstract_html_url" content='https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-5'/>
    
    <meta name="citation_fulltext_html_url" content='https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-5'/>
    
    <meta name="citation_journal_title" content='Journal of Hematology &amp; Oncology'/>
    
    <meta name="citation_publisher" content='BioMed Central'/>
    
    <meta name="citation_issn" content='1756-8722'/>
    
    <meta name="citation_title" content='Molecular alterations of isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients'/>
    
    <meta name="citation_volume" content='5'/>
    
    <meta name="citation_issue" content='1'/>
    
    <meta name="citation_date" content='2012/03/07'/>
    
    <meta name="citation_publication_date" content='2012/03/07'/>
    
    <meta name="citation_firstpage" content='5'/>
    
    <meta name="citation_article_type" content='Research'/>
    
    <meta name="citation_fulltext_world_readable" content=''/>
    
    <meta name="dc.creator" content='Sadudee Chotirat'/>
    
    <meta name="dc.creator" content='Wanna Thongnoppakhun'/>
    
    <meta name="dc.creator" content='Orathai Promsuwicha'/>
    
    <meta name="dc.creator" content='Chetsada Boonthimat'/>
    
    <meta name="dc.creator" content='Chirayu U Auewarakul'/>
    
    <meta name="dc.subject" content='Oncology'/>
    
    <meta name="dc.subject" content='Hematology'/>
    
    <meta name="dc.subject" content='Cancer Research'/>
    
    <meta name="citation_author" content='Sadudee Chotirat'/>
    
    <meta name="citation_author_institution" content='Department of Immunology, Mahidol University, Bangkok, Thailand'/>
    
    <meta name="citation_author" content='Wanna Thongnoppakhun'/>
    
    <meta name="citation_author_institution" content='Department of Research and Development, Mahidol University, Bangkok, Thailand'/>
    
    <meta name="citation_author" content='Orathai Promsuwicha'/>
    
    <meta name="citation_author_institution" content='Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand'/>
    
    <meta name="citation_author" content='Chetsada Boonthimat'/>
    
    <meta name="citation_author_institution" content='Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand'/>
    
    <meta name="citation_author" content='Chirayu U Auewarakul'/>
    
    <meta name="citation_author_institution" content='Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand'/>
    
    <meta name="citation_author_institution" content='Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkoknoi, Thailand'/>
    
    <meta name="citation_reference" content='citation_journal_title=Lancet; citation_title=Acute myeloid leukaemia; citation_author=E Estey; citation_author=H Dohner; citation_volume=368; citation_publication_date=2006; citation_pages=1894-1907; citation_doi=10.1016/S0140-6736(06)69780-8; citation_id=CR1;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood Rev; citation_title=Cytogenetics in acute leukemia; citation_author=K Mrozek; citation_author=NA Heerema; citation_author=CD Bloomfield; citation_volume=18; citation_publication_date=2004; citation_pages=115-136; citation_doi=10.1016/S0268-960X(03)00040-7; citation_id=CR2;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Hematol Oncol; citation_title=Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications; citation_author=S Takahashi; citation_volume=4; citation_publication_date=2011; citation_pages=13; citation_doi=10.1186/1756-8722-4-13; citation_id=CR3;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Hematol Oncol; citation_title=Current findings for recurring mutations in acute myeloid leukemia; citation_author=S Takahashi; citation_volume=4; citation_publication_date=2011; citation_pages=36; citation_doi=10.1186/1756-8722-4-36; citation_id=CR4;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Recurring mutations found by sequencing an acute myeloid leukemia genome; citation_author=ER Mardis; citation_author=L Ding; citation_author=DJ Dooling; citation_author=DE Larson; citation_author=MD McLellan; citation_author=K Chen; citation_author=DC Koboldt; citation_author=RS Fulton; citation_author=KD Delehaunty; citation_author=SD McGrath; citation_volume=361; citation_publication_date=2009; citation_pages=1058-1066; citation_doi=10.1056/NEJMoa0903840; citation_id=CR5;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Am J Physiol Cell Physiol; citation_title=Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation; citation_author=JJ Briere; citation_author=J Favier; citation_author=AP Gimenez-Roqueplo; citation_author=P Rustin; citation_volume=291; citation_publication_date=2006; citation_pages=C1114-C1120; citation_doi=10.1152/ajpcell.00216.2006; citation_id=CR6;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nutr Metab (Lond); citation_title=Cancer as a metabolic disease; citation_author=TN Seyfried; citation_author=LM Shelton; citation_volume=7; citation_publication_date=2010; citation_pages=7; citation_doi=10.1186/1743-7075-7-7; citation_id=CR7;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Nature; citation_title=Cancer-associated IDH1 mutations produce 2-hydroxyglutarate; citation_author=L Dang; citation_author=DW White; citation_author=S Gross; citation_author=BD Bennett; citation_author=MA Bittinger; citation_author=EM Driggers; citation_author=VR Fantin; citation_author=HG Jang; citation_author=S Jin; citation_author=MC Keenan; citation_volume=462; citation_publication_date=2009; citation_pages=739-744; citation_doi=10.1038/nature08617; citation_id=CR8;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha; citation_author=S Zhao; citation_author=Y Lin; citation_author=W Xu; citation_author=W Jiang; citation_author=Z Zha; citation_author=P Wang; citation_author=W Yu; citation_author=Z Li; citation_author=L Gong; citation_author=Y Peng; citation_volume=324; citation_publication_date=2009; citation_pages=261-265; citation_doi=10.1126/science.1170944; citation_id=CR9;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Plant Physiol; citation_title=Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence; citation_author=FJ Corpas; citation_author=JB Barroso; citation_author=LM Sandalio; citation_author=JM Palma; citation_author=JA Lupianez; citation_author=LA del Rio; citation_volume=121; citation_publication_date=1999; citation_pages=921-928; citation_doi=10.1104/pp.121.3.921; citation_id=CR10;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Trends Mol Med; citation_title=IDH mutations in glioma and acute myeloid leukemia; citation_author=L Dang; citation_author=S Jin; citation_author=SM Su; citation_volume=16; citation_publication_date=2010; citation_pages=387-397; citation_doi=10.1016/j.molmed.2010.07.002; citation_id=CR11;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Science; citation_title=An integrated genomic analysis of human glioblastoma multiforme; citation_author=DW Parsons; citation_author=S Jones; citation_author=X Zhang; citation_author=JC Lin; citation_author=RJ Leary; citation_author=P Angenendt; citation_author=P Mankoo; citation_author=H Carter; citation_author=IM Siu; citation_author=GL Gallia; citation_volume=321; citation_publication_date=2008; citation_pages=1807-1812; citation_doi=10.1126/science.1164382; citation_id=CR12;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=IDH1 and IDH2 mutations in gliomas; citation_author=H Yan; citation_author=DW Parsons; citation_author=G Jin; citation_author=R McLendon; citation_author=BA Rasheed; citation_author=W Yuan; citation_author=I Kos; citation_author=I Batinic-Haberle; citation_author=S Jones; citation_author=GJ Riggins; citation_volume=360; citation_publication_date=2009; citation_pages=765-773; citation_doi=10.1056/NEJMoa0808710; citation_id=CR13;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Hum Mutat; citation_title=IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors; citation_author=FE Bleeker; citation_author=S Lamba; citation_author=S Leenstra; citation_author=D Troost; citation_author=T Hulsebos; citation_author=WP Vandertop; citation_author=M Frattini; citation_author=F Molinari; citation_author=M Knowles; citation_author=A Cerrato; citation_volume=30; citation_publication_date=2009; citation_pages=7-11; citation_doi=10.1002/humu.20937; citation_id=CR14;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study; citation_author=G Marcucci; citation_author=K Maharry; citation_author=YZ Wu; citation_author=MD Radmacher; citation_author=K Mrozek; citation_author=D Margeson; citation_author=KB Holland; citation_author=SP Whitman; citation_author=H Becker; citation_author=S Schwind; citation_volume=28; citation_publication_date=2010; citation_pages=2348-2355; citation_doi=10.1200/JCO.2009.27.3730; citation_id=CR15;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms; citation_author=A Pardanani; citation_author=TL Lasho; citation_author=CM Finke; citation_author=M Mai; citation_author=RF McClure; citation_author=A Tefferi; citation_volume=24; citation_publication_date=2010; citation_pages=1146-1151; citation_doi=10.1038/leu.2010.77; citation_id=CR16;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms; citation_author=O Kosmider; citation_author=V Gelsi-Boyer; citation_author=L Slama; citation_author=F Dreyfus; citation_author=O Beyne-Rauzy; citation_author=B Quesnel; citation_author=M Hunault-Berger; citation_author=B Slama; citation_author=N Vey; citation_author=C Lacombe; citation_volume=24; citation_publication_date=2010; citation_pages=1094-1096; citation_doi=10.1038/leu.2010.52; citation_id=CR17;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation; citation_author=WC Chou; citation_author=HA Hou; citation_author=CY Chen; citation_author=JL Tang; citation_author=M Yao; citation_author=W Tsay; citation_author=BS Ko; citation_author=SJ Wu; citation_author=SY Huang; citation_author=SC Hsu; citation_volume=115; citation_publication_date=2010; citation_pages=2749-2754; citation_doi=10.1182/blood-2009-11-253070; citation_id=CR18;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Exp Med; citation_title=Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations; citation_author=S Gross; citation_author=RA Cairns; citation_author=MD Minden; citation_author=EM Driggers; citation_author=MA Bittinger; citation_author=HG Jang; citation_author=M Sasaki; citation_author=S Jin; citation_author=DP Schenkein; citation_author=SM Su; citation_volume=207; citation_publication_date=2010; citation_pages=339-344; citation_doi=10.1084/jem.20092506; citation_id=CR19;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate; citation_author=PS Ward; citation_author=J Patel; citation_author=DR Wise; citation_author=O Abdel-Wahab; citation_author=BD Bennett; citation_author=HA Coller; citation_author=JR Cross; citation_author=VR Fantin; citation_author=CV Hedvat; citation_author=AE Perl; citation_volume=17; citation_publication_date=2010; citation_pages=225-234; citation_doi=10.1016/j.ccr.2010.01.020; citation_id=CR20;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor; citation_author=K Wagner; citation_author=F Damm; citation_author=G Gohring; citation_author=K Gorlich; citation_author=M Heuser; citation_author=I Schafer; citation_author=O Ottmann; citation_author=M Lubbert; citation_author=W Heit; citation_author=L Kanz; citation_volume=28; citation_publication_date=2010; citation_pages=2356-2364; citation_doi=10.1200/JCO.2009.27.6899; citation_id=CR21;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Molecular alterations of the IDH1 gene in AML: a Children&#39;s Oncology Group and Southwest Oncology Group study; citation_author=PA Ho; citation_author=TA Alonzo; citation_author=KJ Kopecky; citation_author=KL Miller; citation_author=J Kuhn; citation_author=R Zeng; citation_author=RB Gerbing; citation_author=SC Raimondi; citation_author=BA Hirsch; citation_author=V Oehler; citation_volume=24; citation_publication_date=2010; citation_pages=909-913; citation_doi=10.1038/leu.2010.56; citation_id=CR22;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia; citation_author=F Thol; citation_author=F Damm; citation_author=K Wagner; citation_author=G Gohring; citation_author=B Schlegelberger; citation_author=D Hoelzer; citation_author=M Lubbert; citation_author=W Heit; citation_author=L Kanz; citation_author=G Schlimok; citation_volume=116; citation_publication_date=2010; citation_pages=614-616; citation_doi=10.1182/blood-2010-03-272146; citation_id=CR23;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value; citation_author=S Abbas; citation_author=S Lugthart; citation_author=FG Kavelaars; citation_author=A Schelen; citation_author=JE Koenders; citation_author=A Zeilemaker; citation_author=WJ van Putten; citation_author=AW Rijneveld; citation_author=B Lowenberg; citation_author=PJ Valk; citation_volume=116; citation_publication_date=2010; citation_pages=2122-2126; citation_doi=10.1182/blood-2009-11-250878; citation_id=CR24;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication; citation_author=P Paschka; citation_author=RF Schlenk; citation_author=VI Gaidzik; citation_author=M Habdank; citation_author=J Kronke; citation_author=L Bullinger; citation_author=D Spath; citation_author=S Kayser; citation_author=M Zucknick; citation_author=K Gotze; citation_volume=28; citation_publication_date=2010; citation_pages=3636-3643; citation_doi=10.1200/JCO.2010.28.3762; citation_id=CR25;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=The prognostic significance of IDH2 mutations in AML depends on the location of the mutation; citation_author=CL Green; citation_author=CM Evans; citation_author=L Zhao; citation_author=RK Hills; citation_author=AK Burnett; citation_author=DC Linch; citation_author=RE Gale; citation_volume=118; citation_publication_date=2011; citation_pages=409-412; citation_doi=10.1182/blood-2010-12-322479; citation_id=CR26;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status; citation_author=S Schnittger; citation_author=C Haferlach; citation_author=M Ulke; citation_author=T Alpermann; citation_author=W Kern; citation_author=T Haferlach; citation_volume=116; citation_publication_date=2010; citation_pages=5486-5496; citation_doi=10.1182/blood-2010-02-267955; citation_id=CR27;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Biochem Biophys Res Commun; citation_title=IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders; citation_author=Y Zou; citation_author=Y Zeng; citation_author=DF Zhang; citation_author=SH Zou; citation_author=YF Cheng; citation_author=YG Yao; citation_volume=402; citation_publication_date=2010; citation_pages=378-383; citation_doi=10.1016/j.bbrc.2010.10.038; citation_id=CR28;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=IDH1 and IDH2 mutations in pediatric acute leukemia; citation_author=AK Andersson; citation_author=DW Miller; citation_author=JA Lynch; citation_author=AS Lemoff; citation_author=Z Cai; citation_author=SB Pounds; citation_author=I Radtke; citation_author=B Yan; citation_author=JD Schuetz; citation_author=JE Rubnitz; citation_volume=25; citation_publication_date=2011; citation_pages=1570-1577; citation_doi=10.1038/leu.2011.133; citation_id=CR29;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Am J Clin Pathol; citation_title=Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features; citation_author=KP Patel; citation_author=F Ravandi; citation_author=D Ma; citation_author=A Paladugu; citation_author=BA Barkoh; citation_author=LJ Medeiros; citation_author=R Luthra; citation_volume=135; citation_publication_date=2011; citation_pages=35-45; citation_doi=10.1309/AJCPD7NR2RMNQDVF; citation_id=CR30;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Clin Biochem; citation_title=Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis; citation_author=J Lin; citation_author=J Qian; citation_author=DM Yao; citation_author=Y Li; citation_author=J Yang; citation_author=Q Chen; citation_author=HY Chai; citation_author=GF Xiao; citation_author=WR Xu; citation_volume=44; citation_publication_date=2011; citation_pages=779-783; citation_doi=10.1016/j.clinbiochem.2011.04.014; citation_id=CR31;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leuk Res; citation_title=Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients; citation_author=Y Zhang; citation_author=H Wei; citation_author=M Wang; citation_author=L Huai; citation_author=Y Mi; citation_author=Y Zhang; citation_author=DT Lin; citation_author=B Liu; citation_author=W Li; citation_author=C Zhou; citation_volume=35; citation_publication_date=2011; citation_pages=1301-1306; citation_doi=10.1016/j.leukres.2011.01.019; citation_id=CR32;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation; citation_author=ME Figueroa; citation_author=O Abdel-Wahab; citation_author=C Lu; citation_author=PS Ward; citation_author=J Patel; citation_author=A Shih; citation_author=Y Li; citation_author=N Bhagwat; citation_author=A Vasanthakumar; citation_author=HF Fernandez; citation_volume=18; citation_publication_date=2010; citation_pages=553-567; citation_doi=10.1016/j.ccr.2010.11.015; citation_id=CR33;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Cell; citation_title=Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate- dependent dioxygenases; citation_author=W Xu; citation_author=H Yang; citation_author=Y Liu; citation_author=Y Yang; citation_author=P Wang; citation_author=SH Kim; citation_author=S Ito; citation_author=C Yang; citation_author=MT Xiao; citation_author=LX Liu; citation_volume=19; citation_publication_date=2011; citation_pages=17-30; citation_doi=10.1016/j.ccr.2010.12.014; citation_id=CR34;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Cancer Genet Cytogenet; citation_title=Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population; citation_author=CU Auewarakul; citation_author=N Sritana; citation_author=C Limwongse; citation_author=W Thongnoppakhun; citation_author=PT Yenchitsomanus; citation_volume=162; citation_publication_date=2005; citation_pages=127-134; citation_doi=10.1016/j.cancergencyto.2005.03.011; citation_id=CR35;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Eur J Haematol; citation_title=Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia; citation_author=CU Auewarakul; citation_author=D Lauhakirti; citation_author=C Tocharoentanaphol; citation_volume=77; citation_publication_date=2006; citation_pages=51-56; citation_doi=10.1111/j.1600-0609.2006.00663.x; citation_id=CR36;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism; citation_author=CU Auewarakul; citation_author=A Leecharendkeat; citation_author=C Tocharoentanaphol; citation_author=O Promsuwicha; citation_author=N Sritana; citation_author=W Thongnoppakhun; citation_volume=92; citation_publication_date=2007; citation_pages=861-862; citation_doi=10.3324/haematol.10914; citation_id=CR37;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations; citation_author=C Boonthimat; citation_author=W Thongnoppakhun; citation_author=CU Auewarakul; citation_volume=93; citation_publication_date=2008; citation_pages=1565-1569; citation_doi=10.3324/haematol.12937; citation_id=CR38;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Thai J Hematol Transf Med; citation_title=Molecular characterization of PML-RAR&#945; fusion gene with acute promyelocytic leukemia (APL) by nested RT-PCR; citation_author=O Promsuwicha; citation_author=W Thongnoppakhun; citation_author=S Wongkhantee; citation_author=C Tocharoentanaphol; citation_author=CU Auewarakul; citation_volume=15; citation_publication_date=2005; citation_pages=247-257; citation_id=CR39;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Am Stat Assoc; citation_title=Nonparametric estimation from incomplete observations; citation_author=E Kaplan; citation_author=P Meier; citation_volume=53; citation_publication_date=1958; citation_pages=457-481; citation_doi=10.1080/01621459.1958.10501452; citation_id=CR40;'/>
    
    <meta name="citation_reference" content='citation_journal_title=J Clin Oncol; citation_title=Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group; citation_author=N Boissel; citation_author=O Nibourel; citation_author=A Renneville; citation_author=C Gardin; citation_author=O Reman; citation_author=N Contentin; citation_author=D Bordessoule; citation_author=C Pautas; citation_author=T de Revel; citation_author=B Quesnel; citation_volume=28; citation_publication_date=2010; citation_pages=3717-3723; citation_doi=10.1200/JCO.2010.28.2285; citation_id=CR41;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Blood; citation_title=Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases; citation_author=RA Mesa; citation_author=CY Li; citation_author=RP Ketterling; citation_author=GS Schroeder; citation_author=RA Knudson; citation_author=A Tefferi; citation_volume=105; citation_publication_date=2005; citation_pages=973-977; citation_doi=10.1182/blood-2004-07-2864; citation_id=CR42;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Haematologica; citation_title=IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis; citation_author=F Thol; citation_author=EM Weissinger; citation_author=J Krauter; citation_author=K Wagner; citation_author=F Damm; citation_author=M Wichmann; citation_author=G Gohring; citation_author=C Schumann; citation_author=G Bug; citation_author=O Ottmann; citation_volume=95; citation_publication_date=2010; citation_pages=1668-1674; citation_doi=10.3324/haematol.2010.025494; citation_id=CR43;'/>
    
    <meta name="citation_reference" content='citation_journal_title=N Engl J Med; citation_title=Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms; citation_author=A Green; citation_author=P Beer; citation_volume=362; citation_publication_date=2010; citation_pages=369-370; citation_doi=10.1056/NEJMc0910063; citation_id=CR44;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q); citation_author=A Pardanani; citation_author=MM Patnaik; citation_author=TL Lasho; citation_author=M Mai; citation_author=RA Knudson; citation_author=C Finke; citation_author=RP Ketterling; citation_author=RF McClure; citation_author=A Tefferi; citation_volume=24; citation_publication_date=2010; citation_pages=1370-1372; citation_doi=10.1038/leu.2010.98; citation_id=CR45;'/>
    
    <meta name="citation_reference" content='citation_journal_title=Leukemia; citation_title=IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis; citation_author=A Tefferi; citation_author=TL Lasho; citation_author=O Abdel-Wahab; citation_author=P Guglielmelli; citation_author=J Patel; citation_author=D Caramazza; citation_author=L Pieri; citation_author=CM Finke; citation_author=O Kilpivaara; citation_author=M Wadleigh; citation_volume=24; citation_publication_date=2010; citation_pages=1302-1309; citation_doi=10.1038/leu.2010.113; citation_id=CR46;'/>
    
    <meta name="prism.doi" content='10.1186/1756-8722-5-5'/>
    
    <meta name="dc.identifier" content='10.1186/1756-8722-5-5'/>
    
    <meta name="citation_doi" content='10.1186/1756-8722-5-5'/>
    
    <meta name="citation_abstract" content='&lt;h2&gt;Abstract&lt;/h2&gt; &lt;h3&gt;Background&lt;/h3&gt; Isocitrate dehydrogenase 1 and 2 (&lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt;) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to &#945;-ketoglutarate. Acquired somatic mutations of &lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt; have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases.  &lt;h3&gt;Methods&lt;/h3&gt; Two-hundred and thirty newly diagnosed AML patients were analyzed for the presence of &lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt; heterozygous mutations by polymerase chain reaction-denaturing high performance liquid chromatography (PCR-DHPLC) followed by direct sequencing. Clinical and biological characteristics were analyzed and correlated to the &lt;i&gt;IDH&lt;/i&gt; mutational status. Coexisting mutations such as &lt;i&gt;FLT3&lt;/i&gt;, &lt;i&gt;PML-&lt;/i&gt; RARA, &lt;i&gt;RAS&lt;/i&gt;, &lt;i&gt;AML1&lt;/i&gt;, and &lt;i&gt;NPM1&lt;/i&gt; mutations were additionally explored.  &lt;h3&gt;Results&lt;/h3&gt; The prevalence of &lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt; mutations was 8.7% (20/230) and 10.4% (24/230), respectively. Six missense mutations were identified among &lt;i&gt;IDH1&lt;/i&gt;-mutated cases; p.R132H (n = 8), p.R132C (n = 6), p.R132S (n = 2), p.R132G (n = 2), p.R132L (n = 1), and p.I99M (n = 1). Two missense mutations were found in &lt;i&gt;IDH2&lt;/i&gt;-mutated cases; p.R140Q (n = 20) and p.R172K (n = 4). No patients had dual &lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt; mutations. About 18% of AML with normal cytogenetics and 31% of acute promyelocytic leukemia had &lt;i&gt;IDH&lt;/i&gt; mutations. Half of the &lt;i&gt;IDH&lt;/i&gt;-mutated cohort had normal karyotype and the major FAB subtype was AML-M2. Interestingly, &lt;i&gt;IDH1&lt;/i&gt;- and &lt;i&gt;IDH2&lt;/i&gt;-mutated cases predominantly had &lt;i&gt;NPM1&lt;/i&gt; mutations (60-74%) as compared to the wild type (P &amp;lt; 0.001). Very few &lt;i&gt;IDH&lt;/i&gt;-mutated cases had &lt;i&gt;FLT3&lt;/i&gt; and/or &lt;i&gt;RAS&lt;/i&gt; abnormalities and none of them had &lt;i&gt;AML1&lt;/i&gt; mutations. Older age and higher median platelet counts were significantly associated with &lt;i&gt;IDH2&lt;/i&gt; mutations although the clinical impact of either &lt;i&gt;IDH1&lt;/i&gt; or &lt;i&gt;IDH2&lt;/i&gt; mutations on patients&#39; overall survival could not be observed.  &lt;h3&gt;Conclusion&lt;/h3&gt; Overall, 19% of newly diagnosed AML patients had alterations of &lt;i&gt;IDH&lt;/i&gt; genes. No patients concurrently carried both &lt;i&gt;IDH1&lt;/i&gt; and &lt;i&gt;IDH2&lt;/i&gt; mutations suggesting that these mutations were mutually exclusive. &lt;i&gt;NPM1&lt;/i&gt; mutation appears as a major coexisting genetic mutation in &lt;i&gt;IDH&lt;/i&gt;-mutated patients. Our present data failed to support the prognostic relevance of &lt;i&gt;IDH&lt;/i&gt; mutations although alterations of these metabolic genes potentially have an important role in leukemia development.'/>
    
    <meta name="DOI" content='10.1186/1756-8722-5-5'/>
    

        
    <script type="text/javascript">
        dataLayer = [{"content":{"article":{"doi":"10.1186/1756-8722-5-5","articleType":"Research","peerReviewType":"Closed"},"contentInfo":{"imprint":"BioMed Central","title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","publishedAt":1331078400000,"publishedAtDate":"2012-03-07","authors":["Sadudee Chotirat","Wanna Thongnoppakhun","Orathai Promsuwicha","Chetsada Boonthimat","Chirayu U Auewarakul"],"collections":[]},"attributes":{"deliveryPlatform":"oscar","template":null,"cms":null,"copyright":{"creativeCommonsType":null}},"journal":{"volume":"5","issue":"1","title":"Journal of Hematology & Oncology","category":"AJ","id":13045},"category":{"pmc":{"primarySubject":"Medicine & Public Health"}}}}]

    </script>

        

        <meta charset="UTF-8"/>
        <meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <meta name="viewport" content="width=device-width, initial-scale=1"/>
        <!-- For IE 9 and below -->
<!--[if IE]><link rel="shortcut icon" href=/static/images/favicons/biomedcentral/favicon-dc10a51d5f.ico><![endif]-->
<!-- Touch Icons - iOS and Android 2.1+ -->
<link rel="apple-touch-icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
<!-- Firefox, Chrome, Safari, IE 11+ and Opera -->
<link rel="icon" href=/static/images/favicons/biomedcentral/favicon-0969f3a317.png>
        <script>(function(H){H.className=H.className.replace(/\bno-js\b/,'js')})(document.documentElement)</script>
        <script>(function(d) {if (sessionStorage.getItem('webfonts') == 'true'){d.className += ' webfonts-loaded';}})(document.documentElement);</script>
        <link rel="stylesheet" media="screen" href=/static/styles/basic/basic-8a9ed7dce9.css>
<link rel="stylesheet" media="print" href=/static/styles/biomedcentral/biomedcentral-print-9d9c0bc8d5.css>

<link rel="stylesheet" class="js-ctm" href=/static/styles/biomedcentral/biomedcentral-1a58e9106c.css
      media="only screen and (-webkit-min-device-pixel-ratio:0) and (min-color-index:0), (-ms-high-contrast: none), only all and (min--moz-device-pixel-ratio:0) and (min-resolution: 3e1dpcm)">
        
    <script type="text/javascript">
        config = {
            env: 'live',
            site: 'jhoonline.biomedcentral.com',
            siteWithPath: 'jhoonline.biomedcentral.com' + window.location.pathname,
            twitterHashtag: '',
            cmsPrefix: 'http://studio-cms.springer.com/studio/',
            
            doi: '10.1186/1756-8722-5-5',
            figshareScriptUrl: 'https://widgets.figshare.com/static/figshare.js',
            publisherBrand: 'BioMed Central'
        };
    </script>

        
    
    <script>
        window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;

        (function() {
            var sampleRate = 20;

            ga('create', "UA-62062378-21", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate
            });

            ga("set", "anonymizeIp", true);
            ga('send', 'pageview');

        
            ga('create', "UA-54492316-9", {
                cookieDomain: 'none',
                allowLinker: true,
                siteSpeedSampleRate: sampleRate,
                name: 'global'
            });
            ga("global.set", "anonymizeIp", true);
            ga('global.send', 'pageview');
            ga('set', 'transport', 'beacon');
        
        }())
    </script>
    <script async src='https://www.google-analytics.com/analytics.js'></script>
    

        
    
    <link rel="canonical" href="//jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-5"/>
    


        

        
        
    <meta property="og:url" content="https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-5"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Journal of Hematology &amp; Oncology"/>
    <meta property="og:title" content="Molecular alterations of isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients"/>
    <meta property="og:description" content="Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to Î±-ketoglutarate. Acquired somatic mutations of IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases. Two-hundred and thirty newly diagnosed AML patients were analyzed for the presence of IDH1 and IDH2 heterozygous mutations by polymerase chain reaction-denaturing high performance liquid chromatography (PCR-DHPLC) followed by direct sequencing. Clinical and biological characteristics were analyzed and correlated to the IDH mutational status. Coexisting mutations such as FLT3, PML- RARA, RAS, AML1, and NPM1 mutations were additionally explored. The prevalence of IDH1 and IDH2 mutations was 8.7% (20/230) and 10.4% (24/230), respectively. Six missense mutations were identified among IDH1-mutated cases; p.R132H (n &#x3D; 8), p.R132C (n &#x3D; 6), p.R132S (n &#x3D; 2), p.R132G (n &#x3D; 2), p.R132L (n &#x3D; 1), and p.I99M (n &#x3D; 1). Two missense mutations were found in IDH2-mutated cases; p.R140Q (n &#x3D; 20) and p.R172K (n &#x3D; 4). No patients had dual IDH1 and IDH2 mutations. About 18% of AML with normal cytogenetics and 31% of acute promyelocytic leukemia had IDH mutations. Half of the IDH-mutated cohort had normal karyotype and the major FAB subtype was AML-M2. Interestingly, IDH1- and IDH2-mutated cases predominantly had NPM1 mutations (60-74%) as compared to the wild type (P &lt; 0.001). Very few IDH-mutated cases had FLT3 and/or RAS abnormalities and none of them had AML1 mutations. Older age and higher median platelet counts were significantly associated with IDH2 mutations although the clinical impact of either IDH1 or IDH2 mutations on patients&#x27; overall survival could not be observed. Overall, 19% of newly diagnosed AML patients had alterations of IDH genes. No patients concurrently carried both IDH1 and IDH2 mutations suggesting that these mutations were mutually exclusive. NPM1 mutation appears as a major coexisting genetic mutation in IDH-mutated patients. Our present data failed to support the prognostic relevance of IDH mutations although alterations of these metabolic genes potentially have an important role in leukemia development."/>
    <meta property="og:image" content="https://images.springer.com/sgw/journals/medium/13045.jpg"/>

        
    </head>

    <body class="fulltext" >
    
    
        
    

    
    <div class="container" style="height: 0"><div id="wt_refpoint"></div></div>
    <p class="skip-to-main">
    <a class="skip-to-main__link" href="#main">Skip to main content</a>
</p>

    <div id="top">
        
<div id="RealMediaLeaderboard" class="adsbox RealMediaAd Ad Ad--leaderboard" data-position="Top">
    <div class="Ad_content">
        <p class="Ad_label">Advertisement</p>
        
    </div>
</div>


        



         
    <div id="membership-message-loader-desktop" class="placeholder" data-placeholder="/placeholder/v1/membership/message"></div>
    <header class="header" role="banner">
        <div class="header__inner">
            <a id="header-logo" href="//www.biomedcentral.com/" class="logo header__logo" title="BioMed Central">
                <img srcset="/static/images/biomed-central-logo-976eb64772.svg" src="/static/images/biomed-central-logo-5300b47908.png" class="logo__img" alt="Biomed Central" />
            </a>
            <div class="header__right">
                <div class="toggles js-fade-toggle">
                    <p id="loginLink" class="sign-in toggles__item" data-replace="true" data-placeholder="/placeholder/v1/username">
    <a class="sign-in__link" href="//www.biomedcentral.com/login" data-track-event="click" data-event-category="Account" data-event-action="Click Login Link">
        <span class="sign-in__no-js-account-hide">Login
            <span class="sign-in__js-account-hide"> to </span>
        </span>
        <span class="sign-in__js-account-hide sign-in__no-js-capitalise">your account</span>
    </a>
</p>
                    
                    <a href="#globalSearch" class="toggles__item toggles__item--search" data-toggle="search"><span class="sr-only">Search</span></a>
                </div>
                <form role="search" id="globalSearch" class="search search--expandable header__search" method="GET" action="//www.biomedcentral.com/search" data-track-event="submit"
      data-event-category="Search and Results" data-event-action="Submit search" data-event-label="">
    <div class="search__content">
        <label for="publisherSearch" class="sr-only">Search BioMed Central articles</label>
        <input id="publisherSearch" class="search__input" autocomplete="off" role="textbox" name="query" type="text" value="" title="Search BioMed Central" placeholder="Search BioMed Central articles"/>
        <button id="search" class="search__button" type="submit">
            <span class="sr-only">Search</span>
        </button>
        <input type="hidden" name="searchType" value="publisherSearch"/>
    </div>
</form>

            </div>
            
        </div>
    </header>

        <main role="main">
            
            <header class="journal-header" role="banner">
                <div class="journal-header__inner">
                    <h2 class="journal-header__title" id="journalTitle">
                        
                        <a class="journal-header__title-text" href="/">
                            Journal of Hematology & Oncology
                        </a>
                    </h2>
                    
                </div>
                <div class="navbar">
                    <div class="navbar__inner">
                        

                        
                        <nav class="navbar__nav">
                            <h3 class="navbar__menu-toggle" data-toggle="collapse" data-target="journal-menu">
                                <span class="sr-only">Main </span>menu
                            </h3>
                            <ul id="journal-menu" class="navbar__menu" id="siteNavigation" role="menu">
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/'>Home</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/about'>About</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link is-active" href='/articles'>Articles</a>
                                    </li>
                                
                                    <li class="navbar__item" role="menuitem">
                                        <a class="navbar__link" href='/submission-guidelines'>Submission Guidelines</a>
                                    </li>
                                
                            </ul>
                        </nav>
                        
                    </div>
                </div>
                <div class="journal-identity journal-identity--potholes-red">
                    
                </div>
            </header>
            
        
            <div class="container">
                
                <div id="main" class="layout">
                
                    <div class="layout__main--wide" id="main-content">
                        <div class="block" id="Test-ImgSrc">
                            
                            
    <div class="FulltextWrapper">
        <div class="Categories">
            <div class="ArticleCategory">Research</div>
            <div class="OpenAccessLabel">Open Access</div>
            
        </div>
        
    </div>

                            <div class="FulltextWrapper"><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="MainTitleSection"><h1 xmlns="http://www.w3.org/1999/xhtml" class="ArticleTitle" lang="en">Molecular alterations of isocitrate dehydrogenase 1 and 2 (<em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em>) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients</h1></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="AuthorNames" data-author-affiliations="true"><ul class="u-listReset"><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Sadudee&nbsp;Chotirat</span><sup><a href="#Aff1" class="AffiliationID">1</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Wanna&nbsp;Thongnoppakhun</span><sup><a href="#Aff2" class="AffiliationID">2</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Orathai&nbsp;Promsuwicha</span><sup><a href="#Aff3" class="AffiliationID">3</a></sup>, </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Chetsada&nbsp;Boonthimat</span><sup><a href="#Aff3" class="AffiliationID">3</a></sup> and </li><li class="Author" data-jumpto="Aff"><span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AuthorName">Chirayu&nbsp;U&nbsp;Auewarakul</span><sup><a href="#Aff3" class="AffiliationID">3</a>, <a href="#Aff4" class="AffiliationID">4</a></sup><a href="mailto:chirayuaue@yahoo.com" class="EmailAuthor" title="Email author"><span class="ContactIcon" aria-hidden="true"></span><span class="u-srOnly">Email author</span></a></li></ul></div><div xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="ArticleContextInformation"><div class="ContextInformation"><div class="ContextInformationJournalTitles"><span class="ArticleCitation"><span xmlns="http://www.w3.org/1999/xhtml" class="JournalTitle">Journal of Hematology &amp; Oncology</span><span class="ArticleCitation_Year">2012</span><span class="ArticleCitation_Volume"><strong>5</strong>:5</span></span></div><p class="ArticleDOI"><a target="_blank" href="https://doi.org/10.1186/1756-8722-5-5">https://doi.org/10.1186/1756-8722-5-5</a></p><p class="Copyright">Â© &nbsp;Chotirat et al; licensee BioMed Central Ltd.&nbsp;2012</p></div></div><div class="ArticleHistory"><p class="History HistoryReceived"><strong>Received: </strong>31&nbsp;January&nbsp;2012</p><p class="History HistoryAccepted"><strong>Accepted: </strong>7&nbsp;March&nbsp;2012</p><p class="History HistoryOnlineDate"><strong>Published: </strong>7&nbsp;March&nbsp;2012</p></div></div>
                            
                            
                            
    

                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Abstract" id="Abs1" lang="en"><h2 class="Heading js-ToggleCollapseSection">Abstract</h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec1">
                <h3 xmlns="" class="Heading">Background</h3>
                <p class="Para">Isocitrate dehydrogenase 1 and 2 (<em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em>) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to Î±-ketoglutarate. Acquired somatic mutations of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> have recently been reported in some types of brain tumors and a small proportion of acute myeloid leukemia (AML) cases.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec2">
                <h3 xmlns="" class="Heading">Methods</h3>
                <p class="Para">Two-hundred and thirty newly diagnosed AML patients were analyzed for the presence of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> heterozygous mutations by polymerase chain reaction-denaturing high performance liquid chromatography (PCR-DHPLC) followed by direct sequencing. Clinical and biological characteristics were analyzed and correlated to the <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutational status. Coexisting mutations such as <em xmlns="" class="EmphasisTypeItalic">FLT3</em>, <em xmlns="" class="EmphasisTypeItalic">PML-</em> RARA, <em xmlns="" class="EmphasisTypeItalic">RAS</em>, <em xmlns="" class="EmphasisTypeItalic">AML1</em>, and <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations were additionally explored.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec3">
                <h3 xmlns="" class="Heading">Results</h3>
                <p class="Para">The prevalence of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations was 8.7% (20/230) and 10.4% (24/230), respectively. Six missense mutations were identified among <em xmlns="" class="EmphasisTypeItalic">IDH1</em>-mutated cases; p.R132H (n = 8), p.R132C (n = 6), p.R132S (n = 2), p.R132G (n = 2), p.R132L (n = 1), and p.I99M (n = 1). Two missense mutations were found in <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated cases; p.R140Q (n = 20) and p.R172K (n = 4). No patients had dual <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations. About 18% of AML with normal cytogenetics and 31% of acute promyelocytic leukemia had <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations. Half of the <em xmlns="" class="EmphasisTypeItalic">IDH</em>-mutated cohort had normal karyotype and the major FAB subtype was AML-M2. Interestingly, <em xmlns="" class="EmphasisTypeItalic">IDH1</em>- and <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated cases predominantly had <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations (60-74%) as compared to the wild type (P &lt; 0.001). Very few <em xmlns="" class="EmphasisTypeItalic">IDH</em>-mutated cases had <em xmlns="" class="EmphasisTypeItalic">FLT3</em> and/or <em xmlns="" class="EmphasisTypeItalic">RAS</em> abnormalities and none of them had <em xmlns="" class="EmphasisTypeItalic">AML1</em> mutations. Older age and higher median platelet counts were significantly associated with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations although the clinical impact of either <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations on patients' overall survival could not be observed.</p>
              </div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="AbstractSection" id="ASec4">
                <h3 xmlns="" class="Heading">Conclusion</h3>
                <p class="Para">Overall, 19% of newly diagnosed AML patients had alterations of <em xmlns="" class="EmphasisTypeItalic">IDH</em> genes. No patients concurrently carried both <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations suggesting that these mutations were mutually exclusive. <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutation appears as a major coexisting genetic mutation in <em xmlns="" class="EmphasisTypeItalic">IDH</em>-mutated patients. Our present data failed to support the prognostic relevance of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations although alterations of these metabolic genes potentially have an important role in leukemia development.</p>
              </div></div></section><div xmlns:func="http://oscar.fig.bmc.com" class="KeywordGroup" lang="en">
              <h3 xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Heading">Keywords</h3>
              <span class="Keyword">Acute myeloid leukemia</span>
              <span class="Keyword">Isocitrate dehydrogenase</span>
              <span class="Keyword">Metabolic enzymes</span>
              <span class="Keyword">
                <em xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="EmphasisTypeItalic">IDH1</em>
              </span>
              <span class="Keyword">
                <em xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="EmphasisTypeItalic">IDH2</em>
              </span>
              <span class="Keyword">Cooperative mutations</span>
              <span class="Keyword">Normal karyotype</span>
            </div>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec1" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Background</h2><div class="js-CollapseSection"><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Acute myeloid leukemia (AML) is a malignant hematologic disorder characterized by abnormal expansion of differentiation-defective myeloid cells [<span class="CitationRef"><a href="#CR1" data-toggle="citation" data-target="CR1">1</a></span>]. Various chromosomal aberrations have been identified in AML patients and are uniquely associated with distinct clinical entities and prognostic relevance [<span class="CitationRef"><a href="#CR2" data-toggle="citation" data-target="CR2">2</a></span>]. Although 40-50% of AML cases do not carry any detectable chromosomal abnormalities, a fraction of them are found to have mutations of genes that normally function in cell proliferation, differentiation, and survival such as <em xmlns="" class="EmphasisTypeItalic">FLT3</em>, <em xmlns="" class="EmphasisTypeItalic">NPM1</em>, <em xmlns="" class="EmphasisTypeItalic">RAS</em>, <em xmlns="" class="EmphasisTypeItalic">WT1</em>, and <em xmlns="" class="EmphasisTypeItalic">AML1</em>[<span class="CitationRef"><a href="#CR3" data-toggle="citation" data-target="CR3">3</a></span>, <span class="CitationRef"><a href="#CR4" data-toggle="citation" data-target="CR4">4</a></span>]. Moreover, through a rapid whole genome sequencing approach, it is now evident that at least half of the AML cases with normal karyotype have readily identifiable genomic abnormalities [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Alteration of cellular metabolism has recently been proposed as a novel oncogenetic mechanism [<span class="CitationRef"><a href="#CR6" data-toggle="citation" data-target="CR6">6</a></span>, <span class="CitationRef"><a href="#CR7" data-toggle="citation" data-target="CR7">7</a></span>]. Isocitrate dehydrogenase (IDH) is one the enzymes that, if defective, lead to abnormal cellular metabolism [<span class="CitationRef"><a href="#CR8" data-toggle="citation" data-target="CR8">8</a></span>, <span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>]. There are three IDH isoforms; IDH1 is in the cytoplasm whereas IDH2 and IDH3 are localized in the mitochondria [<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>, <span class="CitationRef"><a href="#CR10" data-toggle="citation" data-target="CR10">10</a></span>]. <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> genes encode enzymes that catalyze oxidative decarboxylation of isocitrate into Î±-ketoglutarate (Î±-KG) by utilizing nicotinamide adenine dinucleotide (NAD) or NAD phosphate (NADP) as a cofactor to generate NADH or NADPH, respectively [<span class="CitationRef"><a href="#CR11" data-toggle="citation" data-target="CR11">11</a></span>]. In 2008, a novel mutation of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> gene was firstly described in patients with glioblastoma multiforme (GBM). Subsequent studies additionally identified such mutations in &gt; 70% of young adults with low-grade glioma and 80% of patients with secondary GBM [<span class="CitationRef"><a href="#CR12" data-toggle="citation" data-target="CR12">12</a></span>â<span class="CitationRef"><a href="#CR14" data-toggle="citation" data-target="CR14">14</a></span>]. Meanwhile in 2009, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation was reported in a subset of AML patients lacking specific chromosomal aberrations [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>] and in 2010, <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutation was identified in AML, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>â<span class="CitationRef"><a href="#CR17" data-toggle="citation" data-target="CR17">17</a></span>]. The worldwide frequencies of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations in newly diagnosed AML patients range from 2% to 14% and 1% to 19%, respectively, with the mutations mostly restricted to codon R132 of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and codon R140 of <em xmlns="" class="EmphasisTypeItalic">IDH2</em>[<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>â<span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>]. Biochemical and molecular analyses reveal that mutations at the evolutionarily conserved site of <em xmlns="" class="EmphasisTypeItalic">IDH</em> lead to interruption of the normal ability of enzyme to bind substrates and subsequent acquisition of novel enzymatic activity resulting in a substantial increase of oncometabolite <em xmlns="" class="EmphasisTypeItalic">R</em>(-) -2-hydroxyglutarate (2HG) through Î±-KG conversion [<span class="CitationRef"><a href="#CR8" data-toggle="citation" data-target="CR8">8</a></span>, <span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>]. The accumulation of elevated 2HG induces global DNA hypermethylation and interruption of hematopoietic differentiation [<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In the present study, we aimed to characterize <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations in newly diagnosed AML patients and investigate their correlations to other parameters such as clinical and hematologic characteristics, cytogenetics and additional genetic mutations.</p></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec2" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Methods</h2><div class="js-CollapseSection"><section id="Sec3" class="Section2 RenderAsSection2">
                <h3 class="Heading">Leukemia samples</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Leukemic samples from 230 newly diagnosed AML cases were consecutively recruited into the study. Clinical and biological characteristics were collected including clinical history, complete blood counts, peripheral blood (PB) smear, bone marrow (BM) studies, flow cytometric immunophenotyping, and chromosome analysis. Mononuclear cells (MNC) were isolated from the leukemic samples by Ficoll-Hypaque density-gradient centrifugation and subsequently used for molecular analysis. Twenty consented normal individuals were used as controls. Patients were treated according to the standard AML regimen which included idarubicin and cytarabine induction therapy followed by high-dose cytarabine-based consolidation phase. This study was approved by the Ethical Committee for Human Research, Faculty of Medicine Siriraj Hospital, Mahidol University.</p>
              </section><section id="Sec4" class="Section2 RenderAsSection2">
                <h3 class="Heading">Mutational analysis of <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em></h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Genomic DNA was extracted using standard phenol-chloroform method or Gentra Puregene Blood Kit (Qiagen, Hidden, Germany) according to the manufacturer's protocol. DNA amplicons harbouring exon 4 of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> were amplified by polymerase chain reaction (PCR) using the primer pair; IDHIf (5'-AGCTCTATATGCCATCACTGC-3'), IDH1r (5'-AACATGCAAAATCACATTATTGCC-3'), IDH2f(5'- AATTTTAGGACCCCCGTCTG-3'), and IDH2r (5'-CTGCAGAGACAAGAGGATGG-3') [<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>]. PCR reactions were performed in a total volume of 20 Î¼L containing 50 ng of genomic DNA, PCR master mixture consisting of 1x Phusion<sup>Â®</sup>HF Buffer (F-520), 200 Î¼M dNTPs, 0.5 Î¼M of each primer, 0.02 U/Î¼L Phusion<sup>Â®</sup> DNA polymerase, and Milli-Q water. The PCR was carried out in a Perkins Elmer PCR2400 thermal cycler (Applied Biosystems, Foster City, CA) using the following steps: initial denaturation at 98Â°C for 30 seconds (sec), 35 cycles at 98Â°C for 10 sec, 60Â°C for 30 sec. and 72Â°C for 30 sec, and final extension at 72Â°C for 5 minutes (min). Both amplicons were screened for heterozygous mutations by denaturing high-performance liquid chromatography (DHPLC) on a WAVE 3500HT with DNASep<sup>Â®</sup> HT cartridge technology (Transgenomic Inc, Omaha, NE, USA). The optimized condition and temperature were predicted by the Navigatorâ¢ software to determine chromatographic peak pattern. PCR crude sample was injected into DHPLC column and the optimal temperature for IDH1 was 58.5Â°C and IDH2 was 64Â°C. Each DHPLC chromatogram was compared to a wild-type reference. The sensitivity of our assay was determined by performing a dilution series containing a different percentage (%) of mutant and wild-type IDH concentrations. Abnormal DHPLC peaks could be clearly detected in 50%, 20%, 10%, 5%, and 3.33% dilutions. The mutational chromatograms were re-amplified in an independent PCR reaction and further subjected to direct sequencing. The sequences were compared to the wild-type <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> cDNA (GenBank Accession number, NM_005896.2 and NM_002168.2, respectively) [<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>].</p>
              </section><section id="Sec5" class="Section2 RenderAsSection2">
                <h3 class="Heading">Analysis of additional molecular aberrations</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Mutational analyses of <em xmlns="" class="EmphasisTypeItalic">FLT3</em>, <em xmlns="" class="EmphasisTypeItalic">PML-RARA, RAS</em>, <em xmlns="" class="EmphasisTypeItalic">AML1</em>, and <em xmlns="" class="EmphasisTypeItalic">NPM1</em> were performed according to our previously described method [<span class="CitationRef"><a href="#CR35" data-toggle="citation" data-target="CR35">35</a></span>â<span class="CitationRef"><a href="#CR39" data-toggle="citation" data-target="CR39">39</a></span>]. Briefly, the DNA or RNA was extracted, then the genes of interest were amplified and detected by gel electrophoresis (<em xmlns="" class="EmphasisTypeItalic">FLT3</em>), denaturing high performance liquid chromatography (DHPLC) (<em xmlns="" class="EmphasisTypeItalic">NPM1</em>), single-strand conformational polymorphism (SSCP) (<em xmlns="" class="EmphasisTypeItalic">RAS</em> and <em xmlns="" class="EmphasisTypeItalic">AML1</em>). For <em xmlns="" class="EmphasisTypeItalic">PML</em>-<em xmlns="" class="EmphasisTypeItalic">RARA</em>, the cDNA was synthesized and reverse transcriptase-polymerase chain reaction (RT-PCR) performed.</p>
              </section><section id="Sec6" class="Section2 RenderAsSection2">
                <h3 class="Heading">Statistical analysis</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The relationship between <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations and various patient characteristics such as age, Hb count, WBC count, platelet count, and percentages of blasts was determined by the student <em xmlns="" class="EmphasisTypeItalic">t</em>-test, equal variances not assumed for continuous variables. Categorical variables such as FAB classification, cytogenetics, and test. The Kaplan-Meier method and the log-rank test were utilized to estimate the distribution of OS [<span class="CitationRef"><a href="#CR40" data-toggle="citation" data-target="CR40">40</a></span>]. For all analyses, a p-value of less than 0.05 was considered statistically significant. All reported p-values were 2-sided.</p>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec7" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Results</h2><div class="js-CollapseSection"><section id="Sec8" class="Section2 RenderAsSection2">
                <h3 class="Heading">Frequency and type of <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutations</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In a total cohort of 230 consecutive AML patients (36 acute promyelocytic leukemia (APL) and 194 non-APL), 44 patients with <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutation were identified (19.13%) by DHPLC showing abnormal chromatogram patterns that were different from the wild-type profiles. These mutations were further confirmed by sequencing analysis (Figure <span class="InternalRef"><a href="#Fig1">1</a></span>). Twenty <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations (8.7%) included six missense mutations leading to amino acid (AA) substitution with different frequencies: c.G395A; p.R132H in 8 cases (40.0%), c.C394T; p.R132C in 6 cases (30.0%), c.C394A; p.R132S in 2 cases (10.0%), c.C394G; p.R132G in 2 cases (10.0%), c.G395T; p.R132L in 1 cases (5.0%), and c.A297G; p.I99M in 1 cases (5.0%) (Table <span class="InternalRef"><a href="#Tab1">1</a></span>). In addition, one silent polymorphism (c.315 G &gt; T; <em xmlns="" class="EmphasisTypeItalic">IDH1</em><sup>
                    <em xmlns="" class="EmphasisTypeItalic">G105G</em>
                  </sup> ) was observed in 3 patients (1.30%). Twenty-four <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations (10.4%) included two missense mutations with different frequencies: c.G419A; p.R140Q in 20 cases (83.3%) and c.G515A; p.R172K in 4 cases (16.7%). All patients with the mutations were heterozygous and retained a wild-type allele (Figure <span class="InternalRef"><a href="#Fig1">1</a></span>). No mutated patients harbored dual mutations of both genes, indicating that these mutations are mutually exclusive.<figure xmlns="" class="Figure" id="Fig1"><div xmlns="http://www.w3.org/1999/xhtml" class="MediaObject">
                      <a target="_blank" href="http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1756-8722-5-5/MediaObjects/13045_2012_Article_193_Fig1_HTML.jpg"><img src="http://media.springernature.com/lw785/springer-static/image/art%3A10.1186%2F1756-8722-5-5/MediaObjects/13045_2012_Article_193_Fig1_HTML.jpg"></img></a>
                    </div><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Figure 1</span>
                        <p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">Detection of</strong> <span class="EmphasisTypeBoldItalic">IDH1</span> <strong class="EmphasisTypeBold">and</strong> <span class="EmphasisTypeBoldItalic">IDH2</span> <strong class="EmphasisTypeBold">mutations by DHPLC and direct sequencing analysis</strong>. DHPLC patterns shows a suspicious peak in cases with <em class="EmphasisTypeItalic">IDH1</em> or <em class="EmphasisTypeItalic">IDH2</em> mutations as compared to cases with the wild type (WT); Six missense <em class="EmphasisTypeItalic">IDH1</em> mutations; R132H, R132C, R132S, R132G, R132L, and I99M and 1 silent mutation (G105G), and 2 missense <em class="EmphasisTypeItalic">IDH2</em> mutations; R140Q and R172K, are demonstrated. (<em class="EmphasisTypeItalic">Abbreviation</em>: C, cysteine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; Q, glutamine; S, serine).</p>
                      </div></figcaption></figure></div>
                <figure id="Tab1" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 1</span>
                      <p xmlns="" class="SimplePara">Type of <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutations identified in 230 AML patients</p>
                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Mutation</p></th><th align="center"><p xmlns="" class="SimplePara">Nucleotide change</p></th><th align="center"><p xmlns="" class="SimplePara">Predicted protein change</p></th><th align="center"><p xmlns="" class="SimplePara">No. of patients</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <em class="EmphasisTypeItalic">IDH1*</em>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.G395A</p></td><td align="center"><p xmlns="" class="SimplePara">CGT-CAT</p></td><td align="center"><p xmlns="" class="SimplePara">p.R132H</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.C394T</p></td><td align="center"><p xmlns="" class="SimplePara">CGT-TGT</p></td><td align="center"><p xmlns="" class="SimplePara">p.R132C</p></td><td align="center"><p xmlns="" class="SimplePara">6</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.C394A</p></td><td align="center"><p xmlns="" class="SimplePara">CGT-AGT</p></td><td align="center"><p xmlns="" class="SimplePara">p.R132S</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.C394G</p></td><td align="center"><p xmlns="" class="SimplePara">CGT-GGT</p></td><td align="center"><p xmlns="" class="SimplePara">p.R132G</p></td><td align="center"><p xmlns="" class="SimplePara">2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.G395T</p></td><td align="center"><p xmlns="" class="SimplePara">CGT-CTT</p></td><td align="center"><p xmlns="" class="SimplePara">p.R132L</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.A297G</p></td><td align="center"><p xmlns="" class="SimplePara">ATA-ATG</p></td><td align="center"><p xmlns="" class="SimplePara">p.I99M</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <em class="EmphasisTypeItalic">IDH2**</em>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.G419A</p></td><td align="center"><p xmlns="" class="SimplePara">CGG-CAG</p></td><td align="center"><p xmlns="" class="SimplePara">p.R140Q</p></td><td align="center"><p xmlns="" class="SimplePara">20</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââc.G515A</p></td><td align="center"><p xmlns="" class="SimplePara">AGG-AAG</p></td><td align="center"><p xmlns="" class="SimplePara">p.R172K</p></td><td align="center"><p xmlns="" class="SimplePara">4</p></td></tr></tbody></table></div><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                    <p xmlns="" class="SimplePara"><em class="EmphasisTypeItalic">Abbreviation:</em> AML, acute myeloid leukemia; C, cysteine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; Q, glutamine; S, serine</p>
                    <p xmlns="" class="SimplePara">*<em class="EmphasisTypeItalic">IDH1</em> nucleotide numbering based upon the National Center for Biotechnology Information sequence NM_005896.2</p>
                    <p xmlns="" class="SimplePara">**<em class="EmphasisTypeItalic">IDH2</em> nucleotide numbering based upon the National Center for Biotechnology Information sequence NM_002168.2</p>
                  </div></figure>
              </section><section id="Sec9" class="Section2 RenderAsSection2">
                <h3 class="Heading">Clinical parameters and morphologic subtypes of patients with <em class="EmphasisTypeItalic">IDH1</em> or <em class="EmphasisTypeItalic">IDH2</em> mutations</h3>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Twenty <em xmlns="" class="EmphasisTypeItalic">IDH1</em>-mutated patients showed no significant differences in age, hemoglobin level, WBC counts, platelet counts or percentages of blasts as compared to the <em xmlns="" class="EmphasisTypeItalic">IDH1</em> wild-type group, although a trend towards more females was observed (15 females vs 5 males; <em xmlns="" class="EmphasisTypeItalic">P</em> = .058). Twenty-four <em xmlns="" class="EmphasisTypeItalic">IDH2-</em> mutated patients also showed no significant differences in sex, WBC counts or percentages of blasts but an older age (49.5-year vs. 43-year; <em xmlns="" class="EmphasisTypeItalic">P</em> = .001), a higher platelet count (59 vs. 45 Ã 10<sup>9</sup>/L; <em xmlns="" class="EmphasisTypeItalic">P</em> = .048), and a trend towards higher hemoglobin level (9.25 g/dL vs. 7.7 g/dL; <em xmlns="" class="EmphasisTypeItalic">P</em> = .059) were observed in the <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated group as compared to the wild-type group (Tables <span class="InternalRef"><a href="#Tab2">2</a></span> and <span class="InternalRef"><a href="#Tab3">3</a></span>). Among <em xmlns="" class="EmphasisTypeItalic">IDH1</em>-mutated cases, the majority was classified as AML with maturation (AML M2) (13/20 cases, 65%) followed by APL (5/20 cases, 25%). None of the cases with APL, acute monoblastic or monocytic leukemia, acute erythroid leukemia, and acute megakaryoblastic leukemia was found among <em xmlns="" class="EmphasisTypeItalic">IDH1</em>-mutated group. Similarly, AML with maturation (AML M2) was the most common subtype among the <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated group (11/24 cases, 46%) (Table <span class="InternalRef"><a href="#Tab3">3</a></span>). The second most common subtypes were APL (6/24 cases, 25%) and acute myelomonocytic leukemia (6/24 cases, 25%). The OS of patients with or without <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations did not differ among the entire series of AML patients and AML patients with normal cytogenetics (<em xmlns="" class="EmphasisTypeItalic">P</em> = 0.200 and 0.272, respectively). No significant difference was demonstrated in subgroups of younger patients (age &lt; 60) and patients with/without additional mutations as compared to the wild-type patients (<em xmlns="" class="EmphasisTypeItalic">P</em> = 0.471 and 0.812, respectively).<figure xmlns="" id="Tab2" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 2</span>
                        <p xmlns="" class="SimplePara">Characteristics of AML patients with a wild type or mutated IDH1</p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Variable</p></th><th align="left"><p xmlns="" class="SimplePara">All cases</p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">IDH1</span>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <span xmlns="" class="EmphasisTypeBoldItalic">m</span>
                              </sup>
                            </p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">IDH1</span>
                              <sup xmlns="http://www.w3.org/1999/xhtml">wt</sup>
                            </p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">P*</span>
                            </p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">No. of cases</strong>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">230</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td><td align="left"><p xmlns="" class="SimplePara">210</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">No. of males/females</strong>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">101/129</p></td><td align="left"><p xmlns="" class="SimplePara">5/15</p></td><td align="left"><p xmlns="" class="SimplePara">96/114</p></td><td align="left"><p xmlns="" class="SimplePara">.058</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Age, years</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.860<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">44 (13-86)</p></td><td align="left"><p xmlns="" class="SimplePara">42.5 (15-85)</p></td><td align="left"><p xmlns="" class="SimplePara">45 (13-86)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Hemoglobin, g/dL</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.311<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">7.8 (1.4 -14.5)</p></td><td align="left"><p xmlns="" class="SimplePara">7.4 (2.9 - 10.8)</p></td><td align="left"><p xmlns="" class="SimplePara">7.85(1.4-14.5)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">WBC count, x10</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <strong xmlns="" class="EmphasisTypeBold">9</strong>
                              </sup>
                              <strong class="EmphasisTypeBold">/L</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.323<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">27.7 (0.6 -494.4)</p></td><td align="left"><p xmlns="" class="SimplePara">26.9 (1.0 -190.9)</p></td><td align="left"><p xmlns="" class="SimplePara">27.7 (0.6 -494.4)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Platelet, x10</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <strong xmlns="" class="EmphasisTypeBold">9</strong>
                              </sup>
                              <strong class="EmphasisTypeBold">/L</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.923<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">46 (1.8-965)</p></td><td align="left"><p xmlns="" class="SimplePara">56 (16.9 - 386)</p></td><td align="left"><p xmlns="" class="SimplePara">45.5 (1.8-965)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Percentage of blasts</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.738<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">70.19 (6.69-95.44)</p></td><td align="left"><p xmlns="" class="SimplePara">75.8 (13.3-91.4)</p></td><td align="left"><p xmlns="" class="SimplePara">69.77 (6.69-95.44)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">FAB classification</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM0</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">1 (5)</p></td><td align="left"><p xmlns="" class="SimplePara">2 (0.9)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM1</p></td><td align="left"><p xmlns="" class="SimplePara">51</p></td><td align="left"><p xmlns="" class="SimplePara">1 (5)</p></td><td align="left"><p xmlns="" class="SimplePara">50 (23.8)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM2</p></td><td align="left"><p xmlns="" class="SimplePara">76</p></td><td align="left"><p xmlns="" class="SimplePara">13 (65)</p></td><td align="left"><p xmlns="" class="SimplePara">63 (30)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM3</p></td><td align="left"><p xmlns="" class="SimplePara">36</p></td><td align="left"><p xmlns="" class="SimplePara">5 (25)</p></td><td align="left"><p xmlns="" class="SimplePara">31 (15)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM4</p></td><td align="left"><p xmlns="" class="SimplePara">34</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">34 (16)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM5</p></td><td align="left"><p xmlns="" class="SimplePara">21</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">21 (10)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM6</p></td><td align="left"><p xmlns="" class="SimplePara">8</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">8 (3.8)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM7</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">1 (0.5)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Cytogenetics</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAbnormal</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">ââât(15;17)</p></td><td align="left"><p xmlns="" class="SimplePara">36</p></td><td align="left"><p xmlns="" class="SimplePara">5 (25)</p></td><td align="left"><p xmlns="" class="SimplePara">31 (15)</p></td><td align="left"><p xmlns="" class="SimplePara">.184</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">ââât(8;21)</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">20 (10)</p></td><td align="left"><p xmlns="" class="SimplePara">.149</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââinv(16)</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">3 (1)</p></td><td align="left"><p xmlns="" class="SimplePara">.760</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââtrisomy 8</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">1 (5)</p></td><td align="left"><p xmlns="" class="SimplePara">3 (1)</p></td><td align="left"><p xmlns="" class="SimplePara">.307</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââOther trisomies</p></td><td align="left"><p xmlns="" class="SimplePara">7</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">7 (3)</p></td><td align="left"><p xmlns="" class="SimplePara">.524</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAll others including monosomies, deletions or combination of these</p></td><td align="left"><p xmlns="" class="SimplePara">22</p></td><td align="left"><p xmlns="" class="SimplePara">2 (10)</p></td><td align="left"><p xmlns="" class="SimplePara">20 (10)</p></td><td align="left"><p xmlns="" class="SimplePara">.594</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââComplex karyotype</p></td><td align="left"><p xmlns="" class="SimplePara">8</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">8 (4)</p></td><td align="left"><p xmlns="" class="SimplePara">.477</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââNormal</p></td><td align="left"><p xmlns="" class="SimplePara">126</p></td><td align="left"><p xmlns="" class="SimplePara">11 (55)</p></td><td align="left"><p xmlns="" class="SimplePara">115 (55)</p></td><td align="left"><p xmlns="" class="SimplePara">.587</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                      <p xmlns="" class="SimplePara">Abbreviation: IDH1<sup xmlns="http://www.w3.org/1999/xhtml">m</sup>, IDH1 mutated; IDH1<sup xmlns="http://www.w3.org/1999/xhtml">wt</sup>, IDH1 wild type</p>
                      <p xmlns="" class="SimplePara">* Fisher exact test unless otherwise indicated; <sup xmlns="http://www.w3.org/1999/xhtml">â </sup>, the student <em class="EmphasisTypeItalic">t</em>- test</p>
                    </div></figure><figure xmlns="" id="Tab3" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 3</span>
                        <p xmlns="" class="SimplePara">Characteristics of AML patients with a wild type or mutated <em class="EmphasisTypeItalic">IDH2</em></p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Variable</p></th><th align="left"><p xmlns="" class="SimplePara">All cases</p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">IDH2</span>
                              <sup xmlns="http://www.w3.org/1999/xhtml">m</sup>
                            </p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">IDH2</span>
                              <sup xmlns="http://www.w3.org/1999/xhtml">wt</sup>
                            </p></th><th align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">P*</span>
                            </p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">No.of cases</strong>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">230</p></td><td align="left"><p xmlns="" class="SimplePara">24</p></td><td align="left"><p xmlns="" class="SimplePara">206</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">No.of males/females</strong>
                            </p></td><td align="left"><p xmlns="" class="SimplePara">101/129</p></td><td align="left"><p xmlns="" class="SimplePara">11/13</p></td><td align="left"><p xmlns="" class="SimplePara">90/116</p></td><td align="left"><p xmlns="" class="SimplePara">.504</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Age, years</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">.001</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">â </sup>
                            </p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">44 (13-86)</p></td><td align="left"><p xmlns="" class="SimplePara">49.5 (38-80)</p></td><td align="left"><p xmlns="" class="SimplePara">43 (13-86)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Hemoglobin, g/dL</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.059<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">7.8 (1.4 - 14.5)</p></td><td align="left"><p xmlns="" class="SimplePara">9.25 (4.7-12.6)</p></td><td align="left"><p xmlns="" class="SimplePara">7.7 (1.4 - 14.5)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">WBC count, Ã 10</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <strong xmlns="" class="EmphasisTypeBold">9</strong>
                              </sup>
                              <strong class="EmphasisTypeBold">/L</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.789<sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">27.7 (0.6 - 494.4)</p></td><td align="left"><p xmlns="" class="SimplePara">29.73 (0.89-222)</p></td><td align="left"><p xmlns="" class="SimplePara">26.4 (0.6 - 494.4)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Platelet, x10</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <strong xmlns="" class="EmphasisTypeBold">9</strong>
                              </sup>
                              <strong class="EmphasisTypeBold">/L</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">.048</strong>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <strong xmlns="" class="EmphasisTypeBold">â </strong>
                              </sup>
                            </p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">46 (1.8-965)</p></td><td align="left"><p xmlns="" class="SimplePara">59 (11-965)</p></td><td align="left"><p xmlns="" class="SimplePara">45 (1.8-852)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Percentage of blasts</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.133 <sup xmlns="http://www.w3.org/1999/xhtml">â </sup></p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMedian (range)</p></td><td align="left"><p xmlns="" class="SimplePara">70.19 (6.69-95.44)</p></td><td align="left"><p xmlns="" class="SimplePara">61.79 (32.52-95.03)</p></td><td align="left"><p xmlns="" class="SimplePara">71.66 (6.69-95.44)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">FAB classification</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM0</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">3 (1.5)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM1</p></td><td align="left"><p xmlns="" class="SimplePara">51</p></td><td align="left"><p xmlns="" class="SimplePara">1 (4)</p></td><td align="left"><p xmlns="" class="SimplePara">50 (24)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM2</p></td><td align="left"><p xmlns="" class="SimplePara">76</p></td><td align="left"><p xmlns="" class="SimplePara">11 (46)</p></td><td align="left"><p xmlns="" class="SimplePara">65 (31)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM3</p></td><td align="left"><p xmlns="" class="SimplePara">36</p></td><td align="left"><p xmlns="" class="SimplePara">6 (25)</p></td><td align="left"><p xmlns="" class="SimplePara">30 (15)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM4</p></td><td align="left"><p xmlns="" class="SimplePara">34</p></td><td align="left"><p xmlns="" class="SimplePara">6 (25)</p></td><td align="left"><p xmlns="" class="SimplePara">28 (14)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM5</p></td><td align="left"><p xmlns="" class="SimplePara">21</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">20 (10)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM6</p></td><td align="left"><p xmlns="" class="SimplePara">8</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">8 (4)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââM7</p></td><td align="left"><p xmlns="" class="SimplePara">1</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">1 (0.5)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td align="left"><p xmlns="" class="SimplePara">Patients (%)</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">Cytogenetics</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAbnormal</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">ââât(15;17)</p></td><td align="left"><p xmlns="" class="SimplePara">36</p></td><td align="left"><p xmlns="" class="SimplePara">6 (25)</p></td><td align="left"><p xmlns="" class="SimplePara">30 (14.6)</p></td><td align="left"><p xmlns="" class="SimplePara">.150</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">ââât(8;21)</p></td><td align="left"><p xmlns="" class="SimplePara">20</p></td><td align="left"><p xmlns="" class="SimplePara">1 (4.2)</p></td><td align="left"><p xmlns="" class="SimplePara">19 (9.2)</p></td><td align="left"><p xmlns="" class="SimplePara">.355</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââinv(16)</p></td><td align="left"><p xmlns="" class="SimplePara">3</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">3 (1.5)</p></td><td align="left"><p xmlns="" class="SimplePara">.717</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââtrisomy 8</p></td><td align="left"><p xmlns="" class="SimplePara">4</p></td><td align="left"><p xmlns="" class="SimplePara">1 (4.2)</p></td><td align="left"><p xmlns="" class="SimplePara">3 (1.5)</p></td><td align="left"><p xmlns="" class="SimplePara">.358</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââOther trisomies</p></td><td align="left"><p xmlns="" class="SimplePara">7</p></td><td align="left"><p xmlns="" class="SimplePara">2<sup xmlns="http://www.w3.org/1999/xhtml">â¡</sup> (8.2)</p></td><td align="left"><p xmlns="" class="SimplePara">5 (2.4)</p></td><td align="left"><p xmlns="" class="SimplePara">.158</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAll others including monosomies, deletions or combination of these</p></td><td align="left"><p xmlns="" class="SimplePara">22</p></td><td align="left"><p xmlns="" class="SimplePara">1 (4.2)</p></td><td align="left"><p xmlns="" class="SimplePara">21 (10.2)</p></td><td align="left"><p xmlns="" class="SimplePara">.301</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââComplex karyotype</p></td><td align="left"><p xmlns="" class="SimplePara">8</p></td><td align="left"><p xmlns="" class="SimplePara">0 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">8 (3.8)</p></td><td align="left"><p xmlns="" class="SimplePara">.408</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââNormal</p></td><td align="left"><p xmlns="" class="SimplePara">126</p></td><td align="left"><p xmlns="" class="SimplePara">12 (50)</p></td><td align="left"><p xmlns="" class="SimplePara">114 (55.3)</p></td><td align="left"><p xmlns="" class="SimplePara">.388</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                      <p xmlns="" class="SimplePara">Abbreviation: IDH2<sup xmlns="http://www.w3.org/1999/xhtml">m</sup>, IDH2 mutated; IDH2<sup xmlns="http://www.w3.org/1999/xhtml">wt</sup>, IDH2 wild type</p>
                      <p xmlns="" class="SimplePara">* Fisher exact test unless otherwise indicated; <sup xmlns="http://www.w3.org/1999/xhtml">â </sup>, Student t- test; <sup xmlns="http://www.w3.org/1999/xhtml">â¡</sup>, 2 cases of trisomy11 harboring IDH2 R172K mutation</p>
                    </div></figure></div>
              </section><section id="Sec10" class="Section2 RenderAsSection2">
                <h3 class="Heading">Chromosomal patterns and additional molecular aberrations in patients with <em class="EmphasisTypeItalic">IDH1</em> or <em class="EmphasisTypeItalic">IDH2</em> mutations</h3>
                <p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Cytogenetic information was available in 226 of 230 patients, 126 patients (55.75%) of whom had normal karyotype and 100 patients (44.25%) had an aberrant karyotype. Of 20 AML cases with <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation, 11 cases had normal karyotype (55%). In the aberrant karyotype, we found 5 cases with t(15;17) chromosome translocation, 2 cases with del(9q), and 1 case with trisomy 8 (Table <span class="InternalRef"><a href="#Tab2">2</a></span>). Of 24 cases with <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutation, 12 cases had normal karyotype (50%). In the aberrant karyotype, we observed 6 cases with t(15;17), 2 cases were <em xmlns="" class="EmphasisTypeItalic">IDH2</em> R172K harboring trisomy 11, 1 case with trisomy 8, 1 case with t(8;21), and 1 case with del(12)(p12.1p13.1) (Table <span class="InternalRef"><a href="#Tab3">3</a></span>).</p>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para"><em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations were significantly associated with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutation as compared with wild-type cases (14/19, 74% vs. 45/185, 24%; <em xmlns="" class="EmphasisTypeItalic">P</em> &lt; 0.001)(Table <span class="InternalRef"><a href="#Tab4">4</a></span>). Some cases had additional mutations including <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD, <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-TKD, <em xmlns="" class="EmphasisTypeItalic">NRAS, and PML-RARA</em>. <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were also significantly associated with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations when compared with the respective wild-type cases (12/20, 60% vs. 47/184, 26%; <em xmlns="" class="EmphasisTypeItalic">P</em> &lt; 0.001)(Table <span class="InternalRef"><a href="#Tab4">4</a></span>). <em xmlns="" class="EmphasisTypeItalic">AML1</em> mutations were not observed in any mutated <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> patients.<figure xmlns="" id="Tab4" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 4</span>
                        <p xmlns="" class="SimplePara">Comparison of additional gene mutations in AML patients with and without <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutations</p>
                      </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col><col></col><col></col><col></col><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Additional gene mutations</p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">IDH1</span>
                              <sup xmlns="http://www.w3.org/1999/xhtml">
                                <span xmlns="" class="EmphasisTypeBoldItalic">m</span>
                              </sup>
                            </p><p xmlns="" class="SimplePara">n = 20 No.</p></th><th align="center"><p xmlns="" class="SimplePara">(%)</p></th><th align="center"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">IDH1</span><sup xmlns="http://www.w3.org/1999/xhtml">
                                <span xmlns="" class="EmphasisTypeBoldItalic">wt</span>
                              </sup> n = 210 No.</p></th><th align="center"><p xmlns="" class="SimplePara">%</p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">P*</span>
                            </p></th><th align="center"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">IDH2</span><sup xmlns="http://www.w3.org/1999/xhtml">
                                <span xmlns="" class="EmphasisTypeBoldItalic">m</span>
                              </sup> n = 24 No.</p></th><th align="center"><p xmlns="" class="SimplePara">%</p></th><th align="center"><p xmlns="" class="SimplePara"><span class="EmphasisTypeBoldItalic">IDH2</span><sup xmlns="http://www.w3.org/1999/xhtml">
                                <span xmlns="" class="EmphasisTypeBoldItalic">wt</span>
                              </sup> n = 206 No.</p></th><th align="center"><p xmlns="" class="SimplePara">%</p></th><th align="center"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">P*</span>
                            </p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">NPM1</span>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">&lt;.001</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">
                              <strong class="EmphasisTypeBold">&lt;.001</strong>
                            </p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââWild type</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">26%</p></td><td align="center"><p xmlns="" class="SimplePara">140</p></td><td align="center"><p xmlns="" class="SimplePara">76%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">40%</p></td><td align="center"><p xmlns="" class="SimplePara">137</p></td><td align="center"><p xmlns="" class="SimplePara">75%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMutated</p></td><td align="center"><p xmlns="" class="SimplePara">14</p></td><td align="center"><p xmlns="" class="SimplePara">74%</p></td><td align="center"><p xmlns="" class="SimplePara">45</p></td><td align="center"><p xmlns="" class="SimplePara">24%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">60%</p></td><td align="center"><p xmlns="" class="SimplePara">47</p></td><td align="center"><p xmlns="" class="SimplePara">25%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">FLT3-</span>
                              <strong class="EmphasisTypeBold">ITD</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.34</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.63</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAbsent</p></td><td align="center"><p xmlns="" class="SimplePara">14</p></td><td align="center"><p xmlns="" class="SimplePara">82%</p></td><td align="center"><p xmlns="" class="SimplePara">108</p></td><td align="center"><p xmlns="" class="SimplePara">74%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">76%</p></td><td align="center"><p xmlns="" class="SimplePara">109</p></td><td align="center"><p xmlns="" class="SimplePara">75%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââPresent</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">18%</p></td><td align="center"><p xmlns="" class="SimplePara">38</p></td><td align="center"><p xmlns="" class="SimplePara">16%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">4</p></td><td align="center"><p xmlns="" class="SimplePara">24%</p></td><td align="center"><p xmlns="" class="SimplePara">37</p></td><td align="center"><p xmlns="" class="SimplePara">25%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">FLT3-</span>
                              <strong class="EmphasisTypeBold">TKD</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.59</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.59</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââAbsent</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">94%</p></td><td align="center"><p xmlns="" class="SimplePara">133</p></td><td align="center"><p xmlns="" class="SimplePara">91%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">94%</p></td><td align="center"><p xmlns="" class="SimplePara">133</p></td><td align="center"><p xmlns="" class="SimplePara">91%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââPresent</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">6%</p></td><td align="center"><p xmlns="" class="SimplePara">33</p></td><td align="center"><p xmlns="" class="SimplePara">9%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">6%</p></td><td align="center"><p xmlns="" class="SimplePara">33</p></td><td align="center"><p xmlns="" class="SimplePara">9%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">AML1</span>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.09</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.09</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââWild type</p></td><td align="center"><p xmlns="" class="SimplePara">15</p></td><td align="center"><p xmlns="" class="SimplePara">100%</p></td><td align="center"><p xmlns="" class="SimplePara">147</p></td><td align="center"><p xmlns="" class="SimplePara">86%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">17</p></td><td align="center"><p xmlns="" class="SimplePara">100%</p></td><td align="center"><p xmlns="" class="SimplePara">145</p></td><td align="center"><p xmlns="" class="SimplePara">86%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMutated</p></td><td align="center"><p xmlns="" class="SimplePara">0</p></td><td align="center"><p xmlns="" class="SimplePara">0%</p></td><td align="center"><p xmlns="" class="SimplePara">23</p></td><td align="center"><p xmlns="" class="SimplePara">14%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">0</p></td><td align="center"><p xmlns="" class="SimplePara">0%</p></td><td align="center"><p xmlns="" class="SimplePara">23</p></td><td align="center"><p xmlns="" class="SimplePara">4%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">NRAS</span>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.49</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.42</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââWild type</p></td><td align="center"><p xmlns="" class="SimplePara">8</p></td><td align="center"><p xmlns="" class="SimplePara">89%</p></td><td align="center"><p xmlns="" class="SimplePara">79</p></td><td align="center"><p xmlns="" class="SimplePara">81%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">9</p></td><td align="center"><p xmlns="" class="SimplePara">90%</p></td><td align="center"><p xmlns="" class="SimplePara">78</p></td><td align="center"><p xmlns="" class="SimplePara">81%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMutated</p></td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">11%</p></td><td align="center"><p xmlns="" class="SimplePara">18</p></td><td align="center"><p xmlns="" class="SimplePara">19%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">1</p></td><td align="center"><p xmlns="" class="SimplePara">10%</p></td><td align="center"><p xmlns="" class="SimplePara">18</p></td><td align="center"><p xmlns="" class="SimplePara">19%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                              <span class="EmphasisTypeBoldItalic">PML</span>
                              <strong class="EmphasisTypeBold">-RARA</strong>
                            </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">.43</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td align="left"><p xmlns="" class="SimplePara">.56</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââWild type</p></td><td align="center"><p xmlns="" class="SimplePara">3</p></td><td align="center"><p xmlns="" class="SimplePara">38%</p></td><td align="center"><p xmlns="" class="SimplePara">12</p></td><td align="center"><p xmlns="" class="SimplePara">28%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">2</p></td><td align="center"><p xmlns="" class="SimplePara">25%</p></td><td align="center"><p xmlns="" class="SimplePara">13</p></td><td align="center"><p xmlns="" class="SimplePara">30%</p></td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">âââMutated</p></td><td align="center"><p xmlns="" class="SimplePara">5</p></td><td align="center"><p xmlns="" class="SimplePara">62%</p></td><td align="center"><p xmlns="" class="SimplePara">31</p></td><td align="center"><p xmlns="" class="SimplePara">72%</p></td><td>&nbsp;</td><td align="center"><p xmlns="" class="SimplePara">6</p></td><td align="center"><p xmlns="" class="SimplePara">75%</p></td><td align="center"><p xmlns="" class="SimplePara">30</p></td><td align="center"><p xmlns="" class="SimplePara">70%</p></td><td>&nbsp;</td></tr></tbody></table></div></figure></div>
              </section></div></section>
            <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="Sec11" class="Section1 RenderAsSection1"><h2 class="Heading js-ToggleCollapseSection">Discussion</h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In the present study, we developed a screening DHPLC method followed by sequencing analysis to detect and confirm the presence of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations in newly diagnosed AML patients. Twenty cases of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations and 24 cases of <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were discovered among the entire newly diagnosed AML cohort. Previous reports from the Asia continent were available from two countries, i.e. Taiwan [<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>] and China [<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>] while the Western studies were from USA [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>, <span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>], Canada [<span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>], France [<span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>], Germany [<span class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>, <span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>], the Netherlands [<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>], and UK [<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>] (Table <span class="InternalRef"><a href="#Tab5">5</a></span>). The overall frequency of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations appears to vary between 2-14% for <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and 1-19% for <em xmlns="" class="EmphasisTypeItalic">IDH2</em> from most Western reports [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]. Worthy of note, the frequency of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations in our population of 8.4% was comparable to 8.5% in the first study reported by Mardis <em xmlns="" class="EmphasisTypeItalic">et al.</em> in 2009 [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>] although these figures were somewhat higher than those of the Chinese AML studies (5.5%, 5.6%, 6.3%, and 3.6%) [<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>, <span class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>]. The frequency of <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations of 10.4% in our cases was also slightly higher than the only available <em xmlns="" class="EmphasisTypeItalic">IDH2</em> study from Asia (8.3%, 4/48) [<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>]. The frequency discrepancies among various studies may reflect the variable inclusion criteria of the study samples, the variable sensitivity of the detection assays, the selective inclusion or exclusion of certain <em xmlns="" class="EmphasisTypeItalic">IDH</em> aberrations or the true racial differences.<figure xmlns="" id="Tab5" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 5</span>
                      <p xmlns="" class="SimplePara">Incidence of <em class="EmphasisTypeItalic">IDH</em> mutations in AML patients from various countries</p>
                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Country</p></th><th align="center"><p xmlns="" class="SimplePara">No. <span class="EmphasisTypeBoldItalic">IDH1m</span>/all cases (%)</p></th><th align="center"><p xmlns="" class="SimplePara">No. of <span class="EmphasisTypeBoldItalic">IDH1m</span>/CN-AML (%)</p></th><th align="center"><p xmlns="" class="SimplePara">No. <span class="EmphasisTypeBoldItalic">IDH2m</span>/all cases (%)</p></th><th align="center"><p xmlns="" class="SimplePara">No. of <span class="EmphasisTypeBoldItalic">IDH2m</span>/CN-AML (%)</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">ASIA</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">Taiwan</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Chou W <em class="EmphasisTypeItalic">et al.</em>(2010) [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>]</p></td><td align="center"><p xmlns="" class="SimplePara">27/493 (5.5)</p></td><td align="center"><p xmlns="" class="SimplePara">20/227 (8.8)</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">China</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Zou Y <em class="EmphasisTypeItalic">et al.</em>(2010) [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>]</p></td><td align="center"><p xmlns="" class="SimplePara">4/68 (5.9)</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td><td align="center"><p xmlns="" class="SimplePara">4/48 (8.3)</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Zhang Y <em class="EmphasisTypeItalic">et al.</em>(2011) [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>]</p></td><td align="center"><p xmlns="" class="SimplePara">23/365 (6.3)</p></td><td align="center"><p xmlns="" class="SimplePara">6/111 (5.4)</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Lin J <em class="EmphasisTypeItalic">et al.</em>(2011) [<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR31" data-toggle="citation" data-target="CR31">31</a></span>]</p></td><td align="center"><p xmlns="" class="SimplePara">4/110 (3.6)</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td><td align="center"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">Thailand</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">This study</p></td><td align="center"><p xmlns="" class="SimplePara">20/230 (8.7)</p></td><td align="center"><p xmlns="" class="SimplePara">11/126 (8.7)</p></td><td align="center"><p xmlns="" class="SimplePara">24/230 (10.4)</p></td><td align="center"><p xmlns="" class="SimplePara">12/126 (9.5)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara"><strong class="EmphasisTypeBold">EUROPE</strong><sup xmlns="http://www.w3.org/1999/xhtml">â¡</sup>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>â<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]</p></td><td align="center"><p xmlns="" class="SimplePara">6.0-10.9</p></td><td align="center"><p xmlns="" class="SimplePara">9.4-16.0</p></td><td align="center"><p xmlns="" class="SimplePara">2.0*-10.9</p></td><td align="center"><p xmlns="" class="SimplePara">3.2*-15.2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">NORTH AMERICA</strong>
                            <sup xmlns="http://www.w3.org/1999/xhtml">
                              <strong xmlns="" class="EmphasisTypeBold">â«</strong>
                            </sup>
                          </p></td><td align="center"><p xmlns="" class="SimplePara">2.2-13.7</p></td><td align="center"><p xmlns="" class="SimplePara">4.9-16.0</p></td><td align="center"><p xmlns="" class="SimplePara">1.3*-19.2</p></td><td align="center"><p xmlns="" class="SimplePara">2.4*-19.2</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR22" data-toggle="citation" data-target="CR22">22</a></span>, <span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>]</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                    <p xmlns="" class="SimplePara">*The authors only identified <em class="EmphasisTypeItalic">IDH2</em> R172K but did not include <em class="EmphasisTypeItalic">IDH2</em> R140Q mutation; <sup xmlns="http://www.w3.org/1999/xhtml">â </sup> Pediatric acute myeloid leukemia; <sup xmlns="http://www.w3.org/1999/xhtml">â¡</sup> All studies reported during 2010-2011; <sup xmlns="http://www.w3.org/1999/xhtml">â«</sup> All studies reported during 2009-2011; ND, not determined</p>
                  </div></figure></div><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para"><em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations consisting of six different amino acid exchanges at p.R132 (n = 19) and p.I99M (n = 1) were identified. Within the p.R132 group, arginine was replaced by histidine (R132H) in most cases (n = 8, 40%), followed by cysteine (R132C; n = 6, 30%), serine (R132S; n = 2, 10%), glycine (R132G; n = 2, 10%) and leucine (R132L, n = 1, 5%). This pattern was extremely different to the mutation pattern reported in glioma, where R132H was predominant observed in 88% of all cases while R132C present in only 4.5% [<span class="CitationRef"><a href="#CR13" data-toggle="citation" data-target="CR13">13</a></span>]. To date, results from structural and functional assays by several multicenter trials suggested that <em xmlns="" class="EmphasisTypeItalic">IDH1</em> R132, which resides at the active site of enzyme substrate affinity, promotes oncogenesis in both glioma and AML [<span class="CitationRef"><a href="#CR9" data-toggle="citation" data-target="CR9">9</a></span>, <span class="CitationRef"><a href="#CR11" data-toggle="citation" data-target="CR11">11</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>]. In the p.I99M case, isoleucine was substituted by methionine which was recently identified as a novel missense mutation in the Chinese cohort by Zou <em xmlns="" class="EmphasisTypeItalic">et al</em>[<span class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>]. The same study revealed that this evolutionary point mutation was also located in the substrate binding site of enzyme and may drive pathogenesis; however, the exact mechanism needs further investigation. In addition, we detected one silent polymorphism (<em xmlns="" class="EmphasisTypeItalic">IDH1</em><sup>G105G</sup>) in 3 cases (1.3%). Wagner <em xmlns="" class="EmphasisTypeItalic">et al.</em>[<span class="CitationRef"><a href="#CR21" data-toggle="citation" data-target="CR21">21</a></span>] previously reported that <em xmlns="" class="EmphasisTypeItalic">IDH1</em><sup>G105G</sup> allele conferred an adverse prognostic impact to patients' survival.</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The identified <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations involved two different types of amino acid substitution spanning exon 4 of the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> gene at arginine 140 and arginine 172. Of note, the former arginine was replaced by glutamine (R140Q; n = 20, 83.3%) and the latter arginine was replaced by lysine (R172K; n = 4, 16.7%). Our study was similar to previous studies which revealed that more than 80% of the <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations involved R140 [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>]. R172 mutations were profoundly associated with biological insights and clinical outcome [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>] while R140 has not been addressed to associate with any prognostic significance in AML [<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>]. Therefore, functional validation should be employed to define whether R140 plays a significant role in AML pathogenesis or is simply a genuine polymorphism.</p><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para"><em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation was previously reported to be strongly associated with normal karyotype or intermediate risk karyotype AML [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]. Noticeably, our present study found that although <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation predominantly had normal karyotype (n = 11/20), various aberrant karyotype were also found (n = 8/20) including 5 cases of t(15;17). Similarly, although half of <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated cases had normal karyotype (n = 12/24), 6 cases had t(15;17). Our study showed a higher frequency of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations in APL with t(15;17) (n = 11/36 cases, 31%) than most other APL series reported [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>, <span class="CitationRef"><a href="#CR32" data-toggle="citation" data-target="CR32">32</a></span>] (Table <span class="InternalRef"><a href="#Tab6">6</a></span>). The prognostic significance of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations in APL patients needs further studies.<figure xmlns="" id="Tab6" class="FigureTable"><figcaption class="Caption" lang="en"><div xmlns="http://www.w3.org/1999/xhtml" class="CaptionContent"><span class="CaptionNumber">Table 6</span>
                      <p xmlns="" class="SimplePara">Reported frequencies of <em class="EmphasisTypeItalic">IDH1</em> and <em class="EmphasisTypeItalic">IDH2</em> mutations in APL patients worldwide</p>
                    </div></figcaption><div class="Table"><table xmlns="http://www.w3.org/1999/xhtml" border="1"><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><thead><tr class="header"><th align="left"><p xmlns="" class="SimplePara">Country</p></th><th align="left"><p xmlns="" class="SimplePara">No. <span class="EmphasisTypeBoldItalic">IDH1m</span>/all cases (%)</p></th><th align="left"><p xmlns="" class="SimplePara">No. of <span class="EmphasisTypeBoldItalic">IDH1m</span> in APL (%)</p></th><th align="left"><p xmlns="" class="SimplePara">No. <span class="EmphasisTypeBoldItalic">IDH2m</span>/all cases (%)</p></th><th align="left"><p xmlns="" class="SimplePara">No. of <span class="EmphasisTypeBoldItalic">IDH2m</span> in APL (%)</p></th></tr></thead><tbody><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">ASIA</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">Taiwan</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Chou W <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">27/493 (5.5)</p></td><td align="left"><p xmlns="" class="SimplePara">0/37 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">China</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Zhang Y <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR28" data-toggle="citation" data-target="CR28">28</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">23/365 (6.3)</p></td><td align="left"><p xmlns="" class="SimplePara">3/77 (3.9)</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">Thailand</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">This study</p></td><td align="left"><p xmlns="" class="SimplePara">20/230 (8.7)</p></td><td align="left"><p xmlns="" class="SimplePara">5/36(13.9)</p></td><td align="left"><p xmlns="" class="SimplePara">24/230 (10.4)</p></td><td align="left"><p xmlns="" class="SimplePara">6/36 (16.7)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">EUROPE</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">Germany</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Schnittger S <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">93/1414 (6.6)</p></td><td align="left"><p xmlns="" class="SimplePara">2/88 (2.3)</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">The Netherlands</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Abbas S <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">55/893 (6.2)</p></td><td align="left"><p xmlns="" class="SimplePara">0/21 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">97/893 (10.9)</p></td><td align="left"><p xmlns="" class="SimplePara">0/21 (0)</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">NORTH AMERICA</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">
                            <strong class="EmphasisTypeBold">United States</strong>
                          </p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Mardis E <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">16/188 (8.5)</p></td><td align="left"><p xmlns="" class="SimplePara">0/16 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td><td align="left"><p xmlns="" class="SimplePara">ND</p></td></tr><tr class="noclass"><td align="left"><p xmlns="" class="SimplePara">Andersson A <em class="EmphasisTypeItalic">et al.</em>[<span xmlns="http://www.w3.org/1999/xhtml" class="CitationRef"><a href="#CR29" data-toggle="citation" data-target="CR29">29</a></span>]</p></td><td align="left"><p xmlns="" class="SimplePara">5/227 (2.2)</p></td><td align="left"><p xmlns="" class="SimplePara">0/7 (0)</p></td><td align="left"><p xmlns="" class="SimplePara">3/227 (1.3)</p></td><td align="left"><p xmlns="" class="SimplePara">0/7 (0)</p></td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="TableFooter">
                    <p xmlns="" class="SimplePara">ND, not determined</p>
                  </div></figure></div><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">To explore if other genetic mutations coexist in AML cases with <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations, we performed mutation analysis of various different genes, i.e. <em xmlns="" class="EmphasisTypeItalic">FLT3</em>, <em xmlns="" class="EmphasisTypeItalic">NPM1</em>, <em xmlns="" class="EmphasisTypeItalic">NRAS</em> and <em xmlns="" class="EmphasisTypeItalic">AML1</em>. <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutations were found to be most frequently accompanied by <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations (74% of the cases; <em xmlns="" class="EmphasisTypeItalic">P</em> &lt; 0.001). Previous studies also demonstrated that <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation was significantly associated with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutation, ranging from 12.5% to 67% as compared to the wild-type <em xmlns="" class="EmphasisTypeItalic">IDH1</em> cases [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]. Similarly, <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were significantly associated with <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutations (60% of the cases; <em xmlns="" class="EmphasisTypeItalic">P</em> &lt; 0.001) which were comparable to other reports [<span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>â<span class="CitationRef"><a href="#CR26" data-toggle="citation" data-target="CR26">26</a></span>]. No significant association was found with other molecular alterations including <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD, <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-TKD, <em xmlns="" class="EmphasisTypeItalic">NRAS</em> and <em xmlns="" class="EmphasisTypeItalic">AML1</em> although <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-ITD was also frequently found co-existing with <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation in some studies [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>]. Meanwhile, other authors also showed no significant correlation between either <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutation and <em xmlns="" class="EmphasisTypeItalic">FLT3</em>-TKD, <em xmlns="" class="EmphasisTypeItalic">NRAS</em> and <em xmlns="" class="EmphasisTypeItalic">AML1</em> mutation [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR24" data-toggle="citation" data-target="CR24">24</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">With respect to clinical and hematologic parameters, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutated cases were frequently females rather than males (15 cases vs. 5 cases) which was similar to the German study by Schnittger <em xmlns="" class="EmphasisTypeItalic">et al.</em>[<span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>]. Interestingly, we observed that both <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were predominantly found in AML with maturation (AML-M2; n = 24/44) and acute promyelocytic leukemia (APL) (AML-M3; n = 11/44) which were different from AML-M1 as reported by others [<span class="CitationRef"><a href="#CR5" data-toggle="citation" data-target="CR5">5</a></span>, <span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR30" data-toggle="citation" data-target="CR30">30</a></span>]. Interestingly, the frequency of <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutation coexisting in AML-M4 of 25% in our study was comparable with 27% in the finding reported by Thol <em xmlns="" class="EmphasisTypeItalic">et al.</em>[<span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>]. <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations did not significantly impact survivals when the whole AML cohort or AML with normal karyotype analyzed (<em xmlns="" class="EmphasisTypeItalic">P</em> = 0.200 and 0.272). We therefore further analyzed OS according to age and <em xmlns="" class="EmphasisTypeItalic">NPM1</em> status. Unfortunately, we could not find a significant difference between <em xmlns="" class="EmphasisTypeItalic">IDH1</em>- and <em xmlns="" class="EmphasisTypeItalic">IDH2</em>-mutated and wild-type cases (<em xmlns="" class="EmphasisTypeItalic">P</em> = 0.471 and .812) either in the younger age group (&lt; 60 years) or the <em xmlns="" class="EmphasisTypeItalic">NPM1</em>-mutated genotype. Our study was consistent with some studies that revealed no impact of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations on the OS of AML cases although other studies suggested that <em xmlns="" class="EmphasisTypeItalic">IDH1</em> or <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations conferred an adverse effect among AML with normal karyotype or AML with favorable genotype (<em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutated/<em xmlns="" class="EmphasisTypeItalic">FLT3</em> wild type) [<span class="CitationRef"><a href="#CR15" data-toggle="citation" data-target="CR15">15</a></span>, <span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>â<span class="CitationRef"><a href="#CR27" data-toggle="citation" data-target="CR27">27</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]. <em xmlns="" class="EmphasisTypeItalic">IDH1</em> mutation conferred a shorter disease-free survival and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> R172 mutation contributed to a lower complete remission or a higher relapse risk compared to wild-type <em xmlns="" class="EmphasisTypeItalic">IDH</em> patients [<span class="CitationRef"><a href="#CR25" data-toggle="citation" data-target="CR25">25</a></span>, <span class="CitationRef"><a href="#CR41" data-toggle="citation" data-target="CR41">41</a></span>]. Our study may be limited by a small number of cases with <em xmlns="" class="EmphasisTypeItalic">IDH</em> alterations and a substantial recruitment of cases with aberrant karyotype [<span class="CitationRef"><a href="#CR18" data-toggle="citation" data-target="CR18">18</a></span>, <span class="CitationRef"><a href="#CR23" data-toggle="citation" data-target="CR23">23</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">The possible oncogenic role of <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations that contribute to AML development has been postulated by available evidence [<span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>]. By structural and functional analysis, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutated cells gained the neomorphic enzymatic activity creating a condition with 2HG oncometabolite accumulation which promotes tumorigenesis through inhibiting a cancer-associated transcription factor such as hypoxia-induced factor (HIF) [<span class="CitationRef"><a href="#CR19" data-toggle="citation" data-target="CR19">19</a></span>, <span class="CitationRef"><a href="#CR20" data-toggle="citation" data-target="CR20">20</a></span>, <span class="CitationRef"><a href="#CR34" data-toggle="citation" data-target="CR34">34</a></span>]. Moreover, inhibition of normal myeloid differentiation and induction of global DNA hypermethylation by mutated <em xmlns="" class="EmphasisTypeItalic">IDH</em> potentially lead to leukemogenesis [<span class="CitationRef"><a href="#CR33" data-toggle="citation" data-target="CR33">33</a></span>], suggesting that <em xmlns="" class="EmphasisTypeItalic">IDH</em> genes and their altered enzymatic pathways may be a potential new target for future drug development for AML patients. Intriguingly, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations were also found in other myeloid disorders such as myeloproliferative neoplasms (MPN) and myelodysplastic syndrome (MDS) which have a propensity to AML development, although at a much lower frequency than AML [<span class="CitationRef"><a href="#CR42" data-toggle="citation" data-target="CR42">42</a></span>, <span class="CitationRef"><a href="#CR43" data-toggle="citation" data-target="CR43">43</a></span>]. It was thus speculated that <em xmlns="" class="EmphasisTypeItalic">IDH</em> mutations were likely to be associated with disease transformation or progression rather than disease initiation [<span class="CitationRef"><a href="#CR44" data-toggle="citation" data-target="CR44">44</a></span>â<span class="CitationRef"><a href="#CR46" data-toggle="citation" data-target="CR46">46</a></span>].</p><p xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">In conclusion, <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations occur in a minor subset of newly diagnosed AML patients with a strong association with normal karyotype, AML-M2 subtype, and <em xmlns="" class="EmphasisTypeItalic">NPM1</em> mutation. No significant correlation with other mutations such as <em xmlns="" class="EmphasisTypeItalic">FLT3</em>, <em xmlns="" class="EmphasisTypeItalic">RAS</em>, and <em xmlns="" class="EmphasisTypeItalic">AML1</em> could be demonstrated. Larger studies are needed to confirm the prognostic impact of <em xmlns="" class="EmphasisTypeItalic">IDH1</em> and <em xmlns="" class="EmphasisTypeItalic">IDH2</em> mutations in AML patients from various ethnic backgrounds. Our results, nevertheless, provide a relevant rationale to utilize these genomic alterations to better characterize AML patients in the future.</p></div></section>
          <section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="Declarations"><h2 class="Heading js-ToggleCollapseSection">
              Declarations
            </h2><div class="js-CollapseSection"><div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Acknowledgments"><h3 xmlns="" class="Heading">Acknowledgements</h3><p xmlns="" class="SimplePara">The authors wish to thank the staff of the Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital for the excellent care of the patients in this study. CUA is currently supported by Siriraj Chalermprakiate Fund, Faculty of Medicine Siriraj Hospital, Mahidol University.</p></div><aside class="Appendix" id="App1">
              
                <h3 class="Heading">Authors' original submitted files for images</h3><div id="widgetContainer"></div>
                <div xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="Para">Below are the links to the authorsâ original submitted files for images.<div class="MediaObject" id="MOESM1">
                    <div xmlns="" class="esm-item "><div xmlns="http://www.w3.org/1999/xhtml" class="caption-container"><a class="filename" href="https://static-content.springer.com/esm/art%3A10.1186%2F1756-8722-5-5/MediaObjects/13045_2012_193_MOESM1_ESM.pdf">13045_2012_193_MOESM1_ESM.pdf</a>
                          <span xmlns="" class="SimplePara">Authorsâ original file for figure 1</span>
                        </div></div>
                  </div></div>
              
            </aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Competing interests</h3><p xmlns="" class="SimplePara">The authors declare that they have no competing interests.</p></aside><aside xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ArticleNote ArticleNoteMisc"><h3 xmlns="" class="Heading">Authors' contributions</h3><p xmlns="" class="SimplePara">SC performed the experiments and data analysis and contributed to the drafting of the manuscript. WT supervised the molecular and data analysis and contributed to the revision of the manuscript. OP and CB contributed to <em class="EmphasisTypeItalic">PML</em>-<em class="EmphasisTypeItalic">RARA</em> and <em class="EmphasisTypeItalic">NPM1</em> mutational analyses. CUA was responsible for the initiation and execution of the entire project and critical revision of the manuscript. All authors read and approved the final manuscript.</p></aside></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 Affiliations" id="Aff"><h2 class="Heading js-ToggleCollapseSection">Authorsâ Affiliations</h2><div class="js-CollapseSection"><div class="Affiliation" id="Aff1"><span class="AffiliationNumber">(1)</span><div class="AffiliationText">Department of Immunology, Mahidol University</div></div><div class="Affiliation" id="Aff2"><span class="AffiliationNumber">(2)</span><div class="AffiliationText">Department of Research and Development, Mahidol University</div></div><div class="Affiliation" id="Aff3"><span class="AffiliationNumber">(3)</span><div class="AffiliationText">Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University</div></div><div class="Affiliation" id="Aff4"><span class="AffiliationNumber">(4)</span><div class="AffiliationText">Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University</div></div></div></section></div>
                            <div class="FulltextWrapper"><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1 SectionTypeMaterialsAndMethods" id="Bib1"><h2 class="Heading js-ToggleCollapseSection">References</h2><div class="js-CollapseSection"><ol class="BibliographyWrapper"><li class="Citation"><cite class="CitationContent" id="CR1">Estey E, Dohner H: Acute myeloid leukaemia. Lancet. 2006, 368: 1894-1907. 10.1016/S0140-6736(06)69780-8.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/S0140-6736(06)69780-8"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17126723"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acute%20myeloid%20leukaemia&amp;author=E.%20Estey&amp;author=H.%20Dohner&amp;journal=Lancet&amp;volume=368&amp;pages=1894-1907&amp;publication_year=2006&amp;doi=10.1016%2FS0140-6736%2806%2969780-8"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR2">Mrozek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev. 2004, 18: 115-136. 10.1016/S0268-960X(03)00040-7.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/S0268-960X(03)00040-7"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15010150"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cytogenetics%20in%20acute%20leukemia&amp;author=K.%20Mrozek&amp;author=NA.%20Heerema&amp;author=CD.%20Bloomfield&amp;journal=Blood%20Rev&amp;volume=18&amp;pages=115-136&amp;publication_year=2004&amp;doi=10.1016%2FS0268-960X%2803%2900040-7"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR3">Takahashi S: Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011, 4: 13-10.1186/1756-8722-4-13.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076284"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/1756-8722-4-13"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21453545"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Downstream%20molecular%20pathways%20of%20FLT3%20in%20the%20pathogenesis%20of%20acute%20myeloid%20leukemia%3A%20biology%20and%20therapeutic%20implications&amp;author=S.%20Takahashi&amp;journal=J%20Hematol%20Oncol&amp;volume=4&amp;pages=13&amp;publication_year=2011&amp;doi=10.1186%2F1756-8722-4-13"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR4">Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011, 4: 36-10.1186/1756-8722-4-36.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180439"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/1756-8722-4-36"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21917154"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Current%20findings%20for%20recurring%20mutations%20in%20acute%20myeloid%20leukemia&amp;author=S.%20Takahashi&amp;journal=J%20Hematol%20Oncol&amp;volume=4&amp;pages=36&amp;publication_year=2011&amp;doi=10.1186%2F1756-8722-4-36"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR5">Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009, 361: 1058-1066. 10.1056/NEJMoa0903840.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201812"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa0903840"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19657110"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Recurring%20mutations%20found%20by%20sequencing%20an%20acute%20myeloid%20leukemia%20genome&amp;author=ER.%20Mardis&amp;author=L.%20Ding&amp;author=DJ.%20Dooling&amp;author=DE.%20Larson&amp;author=MD.%20McLellan&amp;author=K.%20Chen&amp;author=DC.%20Koboldt&amp;author=RS.%20Fulton&amp;author=KD.%20Delehaunty&amp;author=SD.%20McGrath&amp;journal=N%20Engl%20J%20Med&amp;volume=361&amp;pages=1058-1066&amp;publication_year=2009&amp;doi=10.1056%2FNEJMoa0903840"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR6">Briere JJ, Favier J, Gimenez-Roqueplo AP, Rustin P: Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. Am J Physiol Cell Physiol. 2006, 291: C1114-C1120. 10.1152/ajpcell.00216.2006.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1152/ajpcell.00216.2006"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16760265"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Tricarboxylic%20acid%20cycle%20dysfunction%20as%20a%20cause%20of%20human%20diseases%20and%20tumor%20formation&amp;author=JJ.%20Briere&amp;author=J.%20Favier&amp;author=AP.%20Gimenez-Roqueplo&amp;author=P.%20Rustin&amp;journal=Am%20J%20Physiol%20Cell%20Physiol&amp;volume=291&amp;pages=C1114-C1120&amp;publication_year=2006&amp;doi=10.1152%2Fajpcell.00216.2006"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR7">Seyfried TN, Shelton LM: Cancer as a metabolic disease. Nutr Metab (Lond). 2010, 7: 7-10.1186/1743-7075-7-7.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1186/1743-7075-7-7"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer%20as%20a%20metabolic%20disease&amp;author=TN.%20Seyfried&amp;author=LM.%20Shelton&amp;journal=Nutr%20Metab%20%28Lond%29&amp;volume=7&amp;pages=7&amp;publication_year=2010&amp;doi=10.1186%2F1743-7075-7-7"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR8">Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009, 462: 739-744. 10.1038/nature08617.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818760"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/nature08617"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19935646"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer-associated%20IDH1%20mutations%20produce%202-hydroxyglutarate&amp;author=L.%20Dang&amp;author=DW.%20White&amp;author=S.%20Gross&amp;author=BD.%20Bennett&amp;author=MA.%20Bittinger&amp;author=EM.%20Driggers&amp;author=VR.%20Fantin&amp;author=HG.%20Jang&amp;author=S.%20Jin&amp;author=MC.%20Keenan&amp;journal=Nature&amp;volume=462&amp;pages=739-744&amp;publication_year=2009&amp;doi=10.1038%2Fnature08617"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR9">Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009, 324: 261-265. 10.1126/science.1170944.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251015"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1126/science.1170944"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19359588"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Glioma-derived%20mutations%20in%20IDH1%20dominantly%20inhibit%20IDH1%20catalytic%20activity%20and%20induce%20HIF-1alpha&amp;author=S.%20Zhao&amp;author=Y.%20Lin&amp;author=W.%20Xu&amp;author=W.%20Jiang&amp;author=Z.%20Zha&amp;author=P.%20Wang&amp;author=W.%20Yu&amp;author=Z.%20Li&amp;author=L.%20Gong&amp;author=Y.%20Peng&amp;journal=Science&amp;volume=324&amp;pages=261-265&amp;publication_year=2009&amp;doi=10.1126%2Fscience.1170944"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR10">Corpas FJ, Barroso JB, Sandalio LM, Palma JM, Lupianez JA, del Rio LA: Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence. Plant Physiol. 1999, 121: 921-928. 10.1104/pp.121.3.921.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC59455"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1104/pp.121.3.921"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10557241"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Peroxisomal%20NADP-Dependent%20Isocitrate%20Dehydrogenase.%20Characterization%20and%20Activity%20Regulation%20during%20Natural%20Senescence&amp;author=FJ.%20Corpas&amp;author=JB.%20Barroso&amp;author=LM.%20Sandalio&amp;author=JM.%20Palma&amp;author=JA.%20Lupianez&amp;author=LA.%20del%20Rio&amp;journal=Plant%20Physiol&amp;volume=121&amp;pages=921-928&amp;publication_year=1999&amp;doi=10.1104%2Fpp.121.3.921"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR11">Dang L, Jin S, Su SM: IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010, 16: 387-397. 10.1016/j.molmed.2010.07.002.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.molmed.2010.07.002"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20692206"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH%20mutations%20in%20glioma%20and%20acute%20myeloid%20leukemia&amp;author=L.%20Dang&amp;author=S.%20Jin&amp;author=SM.%20Su&amp;journal=Trends%20Mol%20Med&amp;volume=16&amp;pages=387-397&amp;publication_year=2010&amp;doi=10.1016%2Fj.molmed.2010.07.002"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR12">Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321: 1807-1812. 10.1126/science.1164382.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820389"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1126/science.1164382"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18772396"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=An%20integrated%20genomic%20analysis%20of%20human%20glioblastoma%20multiforme&amp;author=DW.%20Parsons&amp;author=S.%20Jones&amp;author=X.%20Zhang&amp;author=JC.%20Lin&amp;author=RJ.%20Leary&amp;author=P.%20Angenendt&amp;author=P.%20Mankoo&amp;author=H.%20Carter&amp;author=IM.%20Siu&amp;author=GL.%20Gallia&amp;journal=Science&amp;volume=321&amp;pages=1807-1812&amp;publication_year=2008&amp;doi=10.1126%2Fscience.1164382"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR13">Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009, 360: 765-773. 10.1056/NEJMoa0808710.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820383"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMoa0808710"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19228619"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20in%20gliomas&amp;author=H.%20Yan&amp;author=DW.%20Parsons&amp;author=G.%20Jin&amp;author=R.%20McLendon&amp;author=BA.%20Rasheed&amp;author=W.%20Yuan&amp;author=I.%20Kos&amp;author=I.%20Batinic-Haberle&amp;author=S.%20Jones&amp;author=GJ.%20Riggins&amp;journal=N%20Engl%20J%20Med&amp;volume=360&amp;pages=765-773&amp;publication_year=2009&amp;doi=10.1056%2FNEJMoa0808710"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR14">Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009, 30: 7-11. 10.1002/humu.20937.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1002/humu.20937"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19117336"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20mutations%20at%20residue%20p.R132%20%28IDH1%28R132%29%29%20occur%20frequently%20in%20high-grade%20gliomas%20but%20not%20in%20other%20solid%20tumors&amp;author=FE.%20Bleeker&amp;author=S.%20Lamba&amp;author=S.%20Leenstra&amp;author=D.%20Troost&amp;author=T.%20Hulsebos&amp;author=WP.%20Vandertop&amp;author=M.%20Frattini&amp;author=F.%20Molinari&amp;author=M.%20Knowles&amp;author=A.%20Cerrato&amp;journal=Hum%20Mutat&amp;volume=30&amp;pages=7-11&amp;publication_year=2009&amp;doi=10.1002%2Fhumu.20937"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR15">Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010, 28: 2348-2355. 10.1200/JCO.2009.27.3730.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881719"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2009.27.3730"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20368543"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20gene%20mutations%20identify%20novel%20molecular%20subsets%20within%20de%20novo%20cytogenetically%20normal%20acute%20myeloid%20leukemia%3A%20a%20Cancer%20and%20Leukemia%20Group%20B%20study&amp;author=G.%20Marcucci&amp;author=K.%20Maharry&amp;author=YZ.%20Wu&amp;author=MD.%20Radmacher&amp;author=K.%20Mrozek&amp;author=D.%20Margeson&amp;author=KB.%20Holland&amp;author=SP.%20Whitman&amp;author=H.%20Becker&amp;author=S.%20Schwind&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=2348-2355&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2009.27.3730"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR16">Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A: IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010, 24: 1146-1151. 10.1038/leu.2010.77.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.77"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20410924"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutation%20analysis%20in%20chronic-%20and%20blast-phase%20myeloproliferative%20neoplasms&amp;author=A.%20Pardanani&amp;author=TL.%20Lasho&amp;author=CM.%20Finke&amp;author=M.%20Mai&amp;author=RF.%20McClure&amp;author=A.%20Tefferi&amp;journal=Leukemia&amp;volume=24&amp;pages=1146-1151&amp;publication_year=2010&amp;doi=10.1038%2Fleu.2010.77"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR17">Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C et al: Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010, 24: 1094-1096. 10.1038/leu.2010.52.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.52"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20376084"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20of%20IDH1%20and%20IDH2%20genes%20in%20early%20and%20accelerated%20phases%20of%20myelodysplastic%20syndromes%20and%20MDS%2Fmyeloproliferative%20neoplasms&amp;author=O.%20Kosmider&amp;author=V.%20Gelsi-Boyer&amp;author=L.%20Slama&amp;author=F.%20Dreyfus&amp;author=O.%20Beyne-Rauzy&amp;author=B.%20Quesnel&amp;author=M.%20Hunault-Berger&amp;author=B.%20Slama&amp;author=N.%20Vey&amp;author=C.%20Lacombe&amp;journal=Leukemia&amp;volume=24&amp;pages=1094-1096&amp;publication_year=2010&amp;doi=10.1038%2Fleu.2010.52"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR18">Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC et al: Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010, 115: 2749-2754. 10.1182/blood-2009-11-253070.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2009-11-253070"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20097881"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Distinct%20clinical%20and%20biologic%20characteristics%20in%20adult%20acute%20myeloid%20leukemia%20bearing%20the%20isocitrate%20dehydrogenase%201%20mutation&amp;author=WC.%20Chou&amp;author=HA.%20Hou&amp;author=CY.%20Chen&amp;author=JL.%20Tang&amp;author=M.%20Yao&amp;author=W.%20Tsay&amp;author=BS.%20Ko&amp;author=SJ.%20Wu&amp;author=SY.%20Huang&amp;author=SC.%20Hsu&amp;journal=Blood&amp;volume=115&amp;pages=2749-2754&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2009-11-253070"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR19">Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM et al: Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010, 207: 339-344. 10.1084/jem.20092506.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822606"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1084/jem.20092506"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20142433"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Cancer-associated%20metabolite%202-hydroxyglutarate%20accumulates%20in%20acute%20myelogenous%20leukemia%20with%20isocitrate%20dehydrogenase%201%20and%202%20mutations&amp;author=S.%20Gross&amp;author=RA.%20Cairns&amp;author=MD.%20Minden&amp;author=EM.%20Driggers&amp;author=MA.%20Bittinger&amp;author=HG.%20Jang&amp;author=M.%20Sasaki&amp;author=S.%20Jin&amp;author=DP.%20Schenkein&amp;author=SM.%20Su&amp;journal=J%20Exp%20Med&amp;volume=207&amp;pages=339-344&amp;publication_year=2010&amp;doi=10.1084%2Fjem.20092506"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR20">Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE et al: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010, 17: 225-234. 10.1016/j.ccr.2010.01.020.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849316"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.01.020"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20171147"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=DR.%20Wise&amp;author=O.%20Abdel-Wahab&amp;author=BD.%20Bennett&amp;author=HA.%20Coller&amp;author=JR.%20Cross&amp;author=VR.%20Fantin&amp;author=CV.%20Hedvat&amp;author=AE.%20Perl&amp;journal=Cancer%20Cell&amp;volume=17&amp;pages=225-234&amp;publication_year=2010&amp;doi=10.1016%2Fj.ccr.2010.01.020"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR21">Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L et al: Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010, 28: 2356-2364. 10.1200/JCO.2009.27.6899.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2009.27.6899"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20368538"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Impact%20of%20IDH1%20R132%20mutations%20and%20an%20IDH1%20single%20nucleotide%20polymorphism%20in%20cytogenetically%20normal%20acute%20myeloid%20leukemia%3A%20SNP%20rs11554137%20is%20an%20adverse%20prognostic%20factor&amp;author=K.%20Wagner&amp;author=F.%20Damm&amp;author=G.%20Gohring&amp;author=K.%20Gorlich&amp;author=M.%20Heuser&amp;author=I.%20Schafer&amp;author=O.%20Ottmann&amp;author=M.%20Lubbert&amp;author=W.%20Heit&amp;author=L.%20Kanz&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=2356-2364&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2009.27.6899"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR22">Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V et al: Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 2010, 24: 909-913. 10.1038/leu.2010.56.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945692"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.56"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20376086"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20alterations%20of%20the%20IDH1%20gene%20in%20AML%3A%20a%20Children%27s%20Oncology%20Group%20and%20Southwest%20Oncology%20Group%20study&amp;author=PA.%20Ho&amp;author=TA.%20Alonzo&amp;author=KJ.%20Kopecky&amp;author=KL.%20Miller&amp;author=J.%20Kuhn&amp;author=R.%20Zeng&amp;author=RB.%20Gerbing&amp;author=SC.%20Raimondi&amp;author=BA.%20Hirsch&amp;author=V.%20Oehler&amp;journal=Leukemia&amp;volume=24&amp;pages=909-913&amp;publication_year=2010&amp;doi=10.1038%2Fleu.2010.56"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR23">Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Heit W, Kanz L, Schlimok G et al: Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010, 116: 614-616. 10.1182/blood-2010-03-272146.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2010-03-272146"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20421455"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20impact%20of%20IDH2%20mutations%20in%20cytogenetically%20normal%20acute%20myeloid%20leukemia&amp;author=F.%20Thol&amp;author=F.%20Damm&amp;author=K.%20Wagner&amp;author=G.%20Gohring&amp;author=B.%20Schlegelberger&amp;author=D.%20Hoelzer&amp;author=M.%20Lubbert&amp;author=W.%20Heit&amp;author=L.%20Kanz&amp;author=G.%20Schlimok&amp;journal=Blood&amp;volume=116&amp;pages=614-616&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2010-03-272146"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR24">Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ: Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010, 116: 2122-2126. 10.1182/blood-2009-11-250878.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2009-11-250878"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20538800"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acquired%20mutations%20in%20the%20genes%20encoding%20IDH1%20and%20IDH2%20both%20are%20recurrent%20aberrations%20in%20acute%20myeloid%20leukemia%3A%20prevalence%20and%20prognostic%20value&amp;author=S.%20Abbas&amp;author=S.%20Lugthart&amp;author=FG.%20Kavelaars&amp;author=A.%20Schelen&amp;author=JE.%20Koenders&amp;author=A.%20Zeilemaker&amp;author=WJ.%20van%20Putten&amp;author=AW.%20Rijneveld&amp;author=B.%20Lowenberg&amp;author=PJ.%20Valk&amp;journal=Blood&amp;volume=116&amp;pages=2122-2126&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2009-11-250878"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR25">Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010, 28: 3636-3643. 10.1200/JCO.2010.28.3762.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2010.28.3762"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20567020"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20are%20frequent%20genetic%20alterations%20in%20acute%20myeloid%20leukemia%20and%20confer%20adverse%20prognosis%20in%20cytogenetically%20normal%20acute%20myeloid%20leukemia%20with%20NPM1%20mutation%20without%20FLT3%20internal%20tandem%20duplication&amp;author=P.%20Paschka&amp;author=RF.%20Schlenk&amp;author=VI.%20Gaidzik&amp;author=M.%20Habdank&amp;author=J.%20Kronke&amp;author=L.%20Bullinger&amp;author=D.%20Spath&amp;author=S.%20Kayser&amp;author=M.%20Zucknick&amp;author=K.%20Gotze&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=3636-3643&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2010.28.3762"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR26">Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, Gale RE: The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011, 118: 409-412. 10.1182/blood-2010-12-322479.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2010-12-322479"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21596855"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=The%20prognostic%20significance%20of%20IDH2%20mutations%20in%20AML%20depends%20on%20the%20location%20of%20the%20mutation&amp;author=CL.%20Green&amp;author=CM.%20Evans&amp;author=L.%20Zhao&amp;author=RK.%20Hills&amp;author=AK.%20Burnett&amp;author=DC.%20Linch&amp;author=RE.%20Gale&amp;journal=Blood&amp;volume=118&amp;pages=409-412&amp;publication_year=2011&amp;doi=10.1182%2Fblood-2010-12-322479"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR27">Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T: IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010, 116: 5486-5496. 10.1182/blood-2010-02-267955.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2010-02-267955"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20805365"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20mutations%20are%20detected%20in%206.6%25%20of%201414%20AML%20patients%20and%20are%20associated%20with%20intermediate%20risk%20karyotype%20and%20unfavorable%20prognosis%20in%20adults%20younger%20than%2060%20years%20and%20unmutated%20NPM1%20status&amp;author=S.%20Schnittger&amp;author=C.%20Haferlach&amp;author=M.%20Ulke&amp;author=T.%20Alpermann&amp;author=W.%20Kern&amp;author=T.%20Haferlach&amp;journal=Blood&amp;volume=116&amp;pages=5486-5496&amp;publication_year=2010&amp;doi=10.1182%2Fblood-2010-02-267955"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR28">Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF, Yao YG: IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun. 2010, 402: 378-383. 10.1016/j.bbrc.2010.10.038.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.bbrc.2010.10.038"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20946881"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20are%20frequent%20in%20Chinese%20patients%20with%20acute%20myeloid%20leukemia%20but%20rare%20in%20other%20types%20of%20hematological%20disorders&amp;author=Y.%20Zou&amp;author=Y.%20Zeng&amp;author=DF.%20Zhang&amp;author=SH.%20Zou&amp;author=YF.%20Cheng&amp;author=YG.%20Yao&amp;journal=Biochem%20Biophys%20Res%20Commun&amp;volume=402&amp;pages=378-383&amp;publication_year=2010&amp;doi=10.1016%2Fj.bbrc.2010.10.038"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR29">Andersson AK, Miller DW, Lynch JA, Lemoff AS, Cai Z, Pounds SB, Radtke I, Yan B, Schuetz JD, Rubnitz JE et al: IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011, 25: 1570-1577. 10.1038/leu.2011.133.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2011.133"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21647154"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutations%20in%20pediatric%20acute%20leukemia&amp;author=AK.%20Andersson&amp;author=DW.%20Miller&amp;author=JA.%20Lynch&amp;author=AS.%20Lemoff&amp;author=Z.%20Cai&amp;author=SB.%20Pounds&amp;author=I.%20Radtke&amp;author=B.%20Yan&amp;author=JD.%20Schuetz&amp;author=JE.%20Rubnitz&amp;journal=Leukemia&amp;volume=25&amp;pages=1570-1577&amp;publication_year=2011&amp;doi=10.1038%2Fleu.2011.133"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR30">Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R: Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011, 135: 35-45. 10.1309/AJCPD7NR2RMNQDVF.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1309/AJCPD7NR2RMNQDVF"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21173122"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Acute%20myeloid%20leukemia%20with%20IDH1%20or%20IDH2%20mutation%3A%20frequency%20and%20clinicopathologic%20features&amp;author=KP.%20Patel&amp;author=F.%20Ravandi&amp;author=D.%20Ma&amp;author=A.%20Paladugu&amp;author=BA.%20Barkoh&amp;author=LJ.%20Medeiros&amp;author=R.%20Luthra&amp;journal=Am%20J%20Clin%20Pathol&amp;volume=135&amp;pages=35-45&amp;publication_year=2011&amp;doi=10.1309%2FAJCPD7NR2RMNQDVF"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR31">Lin J, Qian J, Yao DM, Li Y, Yang J, Chen Q, Chai HY, Xiao GF, Xu WR: Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clin Biochem. 2011, 44: 779-783. 10.1016/j.clinbiochem.2011.04.014.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.clinbiochem.2011.04.014"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21539821"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Rapid%20and%20reliable%20detection%20of%20IDH1%20R132%20mutations%20in%20acute%20myeloid%20leukemia%20using%20high-resolution%20melting%20curve%20analysis&amp;author=J.%20Lin&amp;author=J.%20Qian&amp;author=DM.%20Yao&amp;author=Y.%20Li&amp;author=J.%20Yang&amp;author=Q.%20Chen&amp;author=HY.%20Chai&amp;author=GF.%20Xiao&amp;author=WR.%20Xu&amp;journal=Clin%20Biochem&amp;volume=44&amp;pages=779-783&amp;publication_year=2011&amp;doi=10.1016%2Fj.clinbiochem.2011.04.014"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR32">Zhang Y, Wei H, Wang M, Huai L, Mi Y, Zhang Y, Lin DT, Liu B, Li W, Zhou C et al: Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res. 2011, 35: 1301-1306. 10.1016/j.leukres.2011.01.019.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.leukres.2011.01.019"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21316759"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Some%20novel%20features%20of%20IDH1-mutated%20acute%20myeloid%20leukemia%20revealed%20in%20Chinese%20patients&amp;author=Y.%20Zhang&amp;author=H.%20Wei&amp;author=M.%20Wang&amp;author=L.%20Huai&amp;author=Y.%20Mi&amp;author=Y.%20Zhang&amp;author=DT.%20Lin&amp;author=B.%20Liu&amp;author=W.%20Li&amp;author=C.%20Zhou&amp;journal=Leuk%20Res&amp;volume=35&amp;pages=1301-1306&amp;publication_year=2011&amp;doi=10.1016%2Fj.leukres.2011.01.019"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR33">Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18: 553-567. 10.1016/j.ccr.2010.11.015.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105845"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.11.015"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21130701"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation&amp;author=ME.%20Figueroa&amp;author=O.%20Abdel-Wahab&amp;author=C.%20Lu&amp;author=PS.%20Ward&amp;author=J.%20Patel&amp;author=A.%20Shih&amp;author=Y.%20Li&amp;author=N.%20Bhagwat&amp;author=A.%20Vasanthakumar&amp;author=HF.%20Fernandez&amp;journal=Cancer%20Cell&amp;volume=18&amp;pages=553-567&amp;publication_year=2010&amp;doi=10.1016%2Fj.ccr.2010.11.015"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR34">Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate- dependent dioxygenases. Cancer Cell. 2011, 19: 17-30. 10.1016/j.ccr.2010.12.014.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229304"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.ccr.2010.12.014"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21251613"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Oncometabolite%202-hydroxyglutarate%20is%20a%20competitive%20inhibitor%20of%20alpha-ketoglutarate-%20dependent%20dioxygenases&amp;author=W.%20Xu&amp;author=H.%20Yang&amp;author=Y.%20Liu&amp;author=Y.%20Yang&amp;author=P.%20Wang&amp;author=SH.%20Kim&amp;author=S.%20Ito&amp;author=C.%20Yang&amp;author=MT.%20Xiao&amp;author=LX.%20Liu&amp;journal=Cancer%20Cell&amp;volume=19&amp;pages=17-30&amp;publication_year=2011&amp;doi=10.1016%2Fj.ccr.2010.12.014"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR35">Auewarakul CU, Sritana N, Limwongse C, Thongnoppakhun W, Yenchitsomanus PT: Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet. 2005, 162: 127-134. 10.1016/j.cancergencyto.2005.03.011.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1016/j.cancergencyto.2005.03.011"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16213360"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Mutations%20of%20the%20FLT3%20gene%20in%20adult%20acute%20myeloid%20leukemia%3A%20determination%20of%20incidence%20and%20identification%20of%20a%20novel%20mutation%20in%20a%20Thai%20population&amp;author=CU.%20Auewarakul&amp;author=N.%20Sritana&amp;author=C.%20Limwongse&amp;author=W.%20Thongnoppakhun&amp;author=PT.%20Yenchitsomanus&amp;journal=Cancer%20Genet%20Cytogenet&amp;volume=162&amp;pages=127-134&amp;publication_year=2005&amp;doi=10.1016%2Fj.cancergencyto.2005.03.011"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR36">Auewarakul CU, Lauhakirti D, Tocharoentanaphol C: Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol. 2006, 77: 51-56. 10.1111/j.1600-0609.2006.00663.x.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1111/j.1600-0609.2006.00663.x"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16573741"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Frequency%20of%20RAS%20gene%20mutation%20and%20its%20cooperative%20genetic%20events%20in%20Southeast%20Asian%20adult%20acute%20myeloid%20leukemia&amp;author=CU.%20Auewarakul&amp;author=D.%20Lauhakirti&amp;author=C.%20Tocharoentanaphol&amp;journal=Eur%20J%20Haematol&amp;volume=77&amp;pages=51-56&amp;publication_year=2006&amp;doi=10.1111%2Fj.1600-0609.2006.00663.x"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR37">Auewarakul CU, Leecharendkeat A, Tocharoentanaphol C, Promsuwicha O, Sritana N, Thongnoppakhun W: AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism. Haematologica. 2007, 92: 861-862. 10.3324/haematol.10914.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.3324/haematol.10914"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17550866"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=AML1%20mutation%20and%20its%20coexistence%20with%20different%20transcription%20factor%20gene%20families%20in%20de%20novo%20acute%20myeloid%20leukemia%20%28AML%29%3A%20redundancy%20or%20synergism&amp;author=CU.%20Auewarakul&amp;author=A.%20Leecharendkeat&amp;author=C.%20Tocharoentanaphol&amp;author=O.%20Promsuwicha&amp;author=N.%20Sritana&amp;author=W.%20Thongnoppakhun&amp;journal=Haematologica&amp;volume=92&amp;pages=861-862&amp;publication_year=2007&amp;doi=10.3324%2Fhaematol.10914"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR38">Boonthimat C, Thongnoppakhun W, Auewarakul CU: Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica. 2008, 93: 1565-1569. 10.3324/haematol.12937.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.3324/haematol.12937"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18641025"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Nucleophosmin%20mutation%20in%20Southeast%20Asian%20acute%20myeloid%20leukemia%3A%20eight%20novel%20variants%2C%20FLT3%20coexistence%20and%20prognostic%20impact%20of%20NPM1%2FFLT3%20mutations&amp;author=C.%20Boonthimat&amp;author=W.%20Thongnoppakhun&amp;author=CU.%20Auewarakul&amp;journal=Haematologica&amp;volume=93&amp;pages=1565-1569&amp;publication_year=2008&amp;doi=10.3324%2Fhaematol.12937"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR39">Promsuwicha O, Thongnoppakhun W, Wongkhantee S, Tocharoentanaphol C, Auewarakul CU: Molecular characterization of PML-RARÎ± fusion gene with acute promyelocytic leukemia (APL) by nested RT-PCR. Thai J Hematol Transf Med. 2005, 15: 247-257.<span class="Occurrences"><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Molecular%20characterization%20of%20PML-RAR%CE%B1%20fusion%20gene%20with%20acute%20promyelocytic%20leukemia%20%28APL%29%20by%20nested%20RT-PCR&amp;author=O.%20Promsuwicha&amp;author=W.%20Thongnoppakhun&amp;author=S.%20Wongkhantee&amp;author=C.%20Tocharoentanaphol&amp;author=CU.%20Auewarakul&amp;journal=Thai%20J%20Hematol%20Transf%20Med&amp;volume=15&amp;pages=247-257&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR40">Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1080/01621459.1958.10501452"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Nonparametric%20estimation%20from%20incomplete%20observations&amp;author=E.%20Kaplan&amp;author=P.%20Meier&amp;journal=J%20Am%20Stat%20Assoc&amp;volume=53&amp;pages=457-481&amp;publication_year=1958&amp;doi=10.2307%2F2281868"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR41">Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B et al: Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010, 28: 3717-3723. 10.1200/JCO.2010.28.2285.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1200/JCO.2010.28.2285"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20625116"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20impact%20of%20isocitrate%20dehydrogenase%20enzyme%20isoforms%201%20and%202%20mutations%20in%20acute%20myeloid%20leukemia%3A%20a%20study%20by%20the%20Acute%20Leukemia%20French%20Association%20group&amp;author=N.%20Boissel&amp;author=O.%20Nibourel&amp;author=A.%20Renneville&amp;author=C.%20Gardin&amp;author=O.%20Reman&amp;author=N.%20Contentin&amp;author=D.%20Bordessoule&amp;author=C.%20Pautas&amp;author=T.%20de%20Revel&amp;author=B.%20Quesnel&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=3717-3723&amp;publication_year=2010&amp;doi=10.1200%2FJCO.2010.28.2285"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR42">Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005, 105: 973-977.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1182/blood-2004-07-2864"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15388582"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Leukemic%20transformation%20in%20myelofibrosis%20with%20myeloid%20metaplasia%3A%20a%20single-institution%20experience%20with%2091%20cases&amp;author=RA.%20Mesa&amp;author=CY.%20Li&amp;author=RP.%20Ketterling&amp;author=GS.%20Schroeder&amp;author=RA.%20Knudson&amp;author=A.%20Tefferi&amp;journal=Blood&amp;volume=105&amp;pages=973-977&amp;publication_year=2005"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR43">Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O et al: IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010, 95: 1668-1674. 10.3324/haematol.2010.025494.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948091"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.3324/haematol.2010.025494"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20494930"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20mutations%20in%20patients%20with%20myelodysplastic%20syndromes%20are%20associated%20with%20an%20unfavorable%20prognosis&amp;author=F.%20Thol&amp;author=EM.%20Weissinger&amp;author=J.%20Krauter&amp;author=K.%20Wagner&amp;author=F.%20Damm&amp;author=M.%20Wichmann&amp;author=G.%20Gohring&amp;author=C.%20Schumann&amp;author=G.%20Bug&amp;author=O.%20Ottmann&amp;journal=Haematologica&amp;volume=95&amp;pages=1668-1674&amp;publication_year=2010&amp;doi=10.3324%2Fhaematol.2010.025494"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR44">Green A, Beer P: Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010, 362: 369-370. 10.1056/NEJMc0910063.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1056/NEJMc0910063"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20107228"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Somatic%20mutations%20of%20IDH1%20and%20IDH2%20in%20the%20leukemic%20transformation%20of%20myeloproliferative%20neoplasms&amp;author=A.%20Green&amp;author=P.%20Beer&amp;journal=N%20Engl%20J%20Med&amp;volume=362&amp;pages=369-370&amp;publication_year=2010&amp;doi=10.1056%2FNEJMc0910063"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR45">Pardanani A, Patnaik MM, Lasho TL, Mai M, Knudson RA, Finke C, Ketterling RP, McClure RF, Tefferi A: Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia. 2010, 24: 1370-1372. 10.1038/leu.2010.98.<span class="Occurrences"><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.98"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20485375"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=Recurrent%20IDH%20mutations%20in%20high-risk%20myelodysplastic%20syndrome%20or%20acute%20myeloid%20leukemia%20with%20isolated%20del%285q%29&amp;author=A.%20Pardanani&amp;author=MM.%20Patnaik&amp;author=TL.%20Lasho&amp;author=M.%20Mai&amp;author=RA.%20Knudson&amp;author=C.%20Finke&amp;author=RP.%20Ketterling&amp;author=RF.%20McClure&amp;author=A.%20Tefferi&amp;journal=Leukemia&amp;volume=24&amp;pages=1370-1372&amp;publication_year=2010&amp;doi=10.1038%2Fleu.2010.98"><span><span>Google Scholar</span></span></a></span></span></cite></li><li class="Citation"><cite class="CitationContent" id="CR46">Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010, 24: 1302-1309. 10.1038/leu.2010.113.<span class="Occurrences"><span class="Occurrence OccurrencePMCID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035975"><span><span>PubMed Central</span></span></a></span><span class="Occurrence OccurrenceDOI"><a target="_blank" href="https://doi.org/10.1038/leu.2010.113"><span><span>View Article</span></span></a></span><span class="Occurrence OccurrencePID"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20508616"><span><span>PubMed</span></span></a></span><span class="Occurrence OccurrenceGS"><a target="_blank" href="http://scholar.google.com/scholar_lookup?title=IDH1%20and%20IDH2%20mutation%20studies%20in%201473%20patients%20with%20chronic-%2C%20fibrotic-%20or%20blast-phase%20essential%20thrombocythemia%2C%20polycythemia%20vera%20or%20myelofibrosis&amp;author=A.%20Tefferi&amp;author=TL.%20Lasho&amp;author=O.%20Abdel-Wahab&amp;author=P.%20Guglielmelli&amp;author=J.%20Patel&amp;author=D.%20Caramazza&amp;author=L.%20Pieri&amp;author=CM.%20Finke&amp;author=O.%20Kilpivaara&amp;author=M.%20Wadleigh&amp;journal=Leukemia&amp;volume=24&amp;pages=1302-1309&amp;publication_year=2010&amp;doi=10.1038%2Fleu.2010.113"><span><span>Google Scholar</span></span></a></span></span></cite></li></ol></div></section><section xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" class="Section1 RenderAsSection1" id="CopyrightMessage"><h2 class="Heading js-ToggleCollapseSection">Copyright</h2><div class="js-CollapseSection"><div xmlns="http://www.w3.org/1999/xhtml" class="ArticleCopyright">Â©&nbsp;Chotirat et al; licensee BioMed Central Ltd.&nbsp;2012<div class="CopyrightComment">
                <p xmlns="" class="SimplePara">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<span xmlns:func="http://oscar.fig.bmc.com" xmlns="http://www.w3.org/1999/xhtml" class="ExternalRef"><a href="http://creativecommons.org/licenses/by/2.0"><span class="RefSource">http://creativecommons.org/licenses/by/2.0</span></a></span>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
              </div></div></div></section></div>
                            


                        </div>
                    </div>
                    <div class="layout__sidebar-right" id="main-sidebar">
                        
                        <div class="block">
                            <aside role="complementary">
                                <div class="SideBox">
                                    
    <p class="SideBox_action">
        <a class="SideBox_pdf" id="articlePdf" target="_blank" href="/track/pdf/10.1186/1756-8722-5-5?site&#x3D;jhoonline.biomedcentral.com" data-track-event="click" data-event-category="PDF Download"
           data-event-action="Click download article PDF"
           data-event-label="10.1186/1756-8722-5-5">Download PDF</a>
    </p>

                                    
                                    
    <h3 class="export-citations-button" data-toggle="collapse" data-target="js-exportCitations">Export citations</h3>
    <div id="js-exportCitations" class="export-citations-content panel">
        <div class="panel__section">
            <h4 class="panel__title">Citations & References</h4>
            <ul class="ListDownload" id="articleReferences">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks citations and references"
                       data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=refman&flavour=full">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote citations and references" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=endnote&flavour=full">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef citations and references" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=bibtex&flavour=full">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">Article citation</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks article citations" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=refman&flavour=citation">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote article citations" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=endnote&flavour=citation">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef article citations" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=bibtex&flavour=citation">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
        <div class="panel__section">
            <h4 class="panel__title">References</h4>
            <ul class="ListDownload">
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Papers, Zotero, Reference Manager, RefWorks references" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=refman&flavour=references">Papers, Zotero, Reference Manager, RefWorks <span>(.RIS)</span></a>
                </li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download EndNote references" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=endnote&flavour=references">EndNote <span>(.ENW)</span></a></li>
                <li><a data-track-event="click" data-event-category="Article Page" data-event-action="Download Mendeley, JabRef references" data-event-label="10.1186/1756-8722-5-5"
                       href="http://citation-needed.springer.com/v2/references/10.1186/1756-8722-5-5?format=bibtex&flavour=references">Mendeley, JabRef <span>(.BIB)</span></a></li>
            </ul>
        </div>
    </div>

                                </div>
                                <div class="SideBox">
                                    <nav xmlns="" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:meta="http://www.springer.com/app/meta" id="ArticleNavigation" class="table-of-contents" aria-label="table of contents"><div class="table-of-contents__content" data-sticky="toc"><h3 class="table-of-contents__title is-open" data-toggle="collapse" data-target="tocMenu" data-event-category="Table of Contents" data-track-event="click" data-event-action="Toggle ToC" data-event-label="Toggle" data-toggle-disable-clickoff="true" aria-expanded="true">Table of Contents</h3><ul class="table-of-contents__menu is-open" role="menu" id="tocMenu" aria-expanded="true"><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Abs1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Abstract">Abstract</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Background">Background</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec2" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Methods">Methods</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec7" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Results">Results</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Sec11" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Discussion">Discussion</a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Declarations" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Declarations">
                        Declarations
                      </a></li><li role="menuitem" class="table-of-contents__item"><a class="table-of-contents__link" href="#Bib1" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="References">References</a></li><li role="menuitem" class="table-of-contents__item is-hidden"><a class="table-of-contents__link" href="#comments" data-event-category="Table of Contents" data-track-event="click" data-event-action="Link Clicked" data-event-label="Comments">Comments</a></li></ul></div></nav>
                                </div>
                                <div class="SideBox">
                                    <h3 class="SideBox_title">Metrics</h3>
                                    <ul class="SideBox_list list-stacked list-stacked--small list-stacked--2">
                                        <div id="article-access-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/access-count/10.1186/1756-8722-5-5 #accessCount-container"></div>
                                        <div id="citation-count-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/citation-count/10.1186/1756-8722-5-5 #count-container"></div>
                                        <div id="altmetric-loader" class="placeholder" data-replace="true" data-placeholder="/placeholder/v1/article/altmetric/10.1186/1756-8722-5-5 #altmetric-container"></div>
                                    </ul>
                                </div>
                                
    <div id="sociaMediaShare" class="SideBox">
        <h3 class="SideBox_title">Share this article</h3>
        <ul id="shareButtons" class="share">
            <li class="share__item">
                <button id="shareOnTwitter" class="js-btnShareOnTwitter share__button share__button--twitter" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Twitter" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on Twitter</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnFacebook" class="js-btnShareOnFacebook share__button share__button--facebook" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Facebook" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on Facebook</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnLinkedIn" class="js-btnShareOnLinkedIn share__button share__button--linkedin" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share LinkedIn" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on LinkedIn</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnWeibo" class="js-btnShareOnWeibo share__button share__button--weibo" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Weibo" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on Weibo</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnGooglePlus" class="js-btnShareOnGplus share__button share__button--gplus" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Google+" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on Google Plus</span>
                </button>
            </li>
            <li class="share__item">
                <button id="shareOnReddit" class="js-btnShareOnReddit share__button share__button--reddit" data-track-event="click"
                        data-event-category="Article Page" data-event-action="Share Reddit" data-event-label="10.1186/1756-8722-5-5">
                    <span class="sr-only">Share on Reddit</span>
                </button>
            </li>
        </ul>
    </div>

                                
    

                                
    

                                
    

                                <div class="SideBox">
                                    <h3 class="SideBox_title">Other Actions</h3>
                                    <ul class="list-stacked list-stacked--2 list-stacked--small">
                                        <li class="list-stacked__item">
                                            
    <a data-track-event="click" data-event-category="Article Page" data-event-action="Order article reprints" data-event-label="10.1186/1756-8722-5-5" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186%2F1756-8722-5-5&volume=5&issue=1&title=Molecular+alterations+of+isocitrate+dehydrogenase+1+and+2+%28+IDH1+and+IDH2+%29+metabolic+genes+and+additional+genetic+mutations+in+newly+diagnosed+acute+myeloid+leukemia+patients&author_name=Sadudee+Chotirat&start_page=1&end_page=10">Order reprint</a>

                                        </li>
                                    </ul>
                                </div>
                                
        
    
                            </aside>
                            
    <div id="FulltextAd" class="adsbox Ad Ad--skyscraper">
        <div class="Ad_content">
            <p class="Ad_label">Advertisement</p>
            <span id="pbgrd-43415139"></span>
        </div>
    </div>

                        </div>
                    </div>
                </div>
            </div>
        </main>
        
            <div class="journal-footer">
                <div class="journal-footer__inner">
                    <div class="journal-footer__summary">
                        <h4 class="journal-footer__title">
                            
                            <span class="journal-footer__title-text">Journal of Hematology & Oncology</span>
                        </h4>
                        <p class="journal-footer__issn">ISSN: 1756-8722</p>
                    </div>
                    
                        <div class="journal-footer__contact">
                            <h4 class="journal-footer__contact-title">Contact us</h4>
                            <ul class="journal-footer__contact-list">
                                
                                    <li class="journal-footer__contact-item">Editorial email: <a href="mailto:charles.plomos@springernature.com">charles.plomos@springernature.com</a></li>
                                
                                
                                    <li class="journal-footer__contact-item">Support email: <a href="mailto:info@biomedcentral.com">info@biomedcentral.com</a></li>
                                
                            </ul>
                        </div>
                    
                </div>
            </div>
        
         
    <footer>
        <div class="footer">
            <div class="footer__header">
                <img srcset="/static/images/biomed-central-logo-white-3c6c941205.svg" src="/static/images/biomed-central-logo-white-faac4202d5.png" class="logo__img footer__logo" alt="Biomed Central" />
                
                    <h2 class="footer__menu-title">Publisher Main Menu</h2>
                    <ul class="footer__primary-menu">
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/journals">Explore journals</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/getpublished">Get published</a>
                            </li>
                        
                            <li class="footer__primary-item">
                                <a class="footer__link footer__primary-link" href="//www.biomedcentral.com/about">About BioMed Central</a>
                            </li>
                        
                    </ul>
                
            </div>
            <div id="Test-FooterExists" class="footer__content">
                <div class="footer__legal">
                    
                    <p class="footer__terms">By continuing to use this website, you agree to our <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/terms-and-conditions">Terms and Conditions</a>, <a class="footer__link footer__link--inline"
                                                                                                                                                                                                                               href="//www.biomedcentral.com/terms-and-conditions/privacy-statement">Privacy
                        statement</a> and <a class="footer__link footer__link--inline" href="//www.biomedcentral.com/cookies">Cookies</a> policy.</p>
                </div>
                
    <nav id="publisherFooter" class="footer__nav">
        <h3 class="footer__menu-title">Publisher secondary menu</h3>
        <div class="footer__nav-inner">
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://blogs.biomedcentral.com/">Read more on our blogs</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/login">Receive BMC newsletters</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/account">Manage article alerts</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/language-editing/">Language editing for authors</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="http://authorservices.springernature.com/scientific-editing/">Scientific editing for authors</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/policies">Policies</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/accessibility">Accessibility</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/press-centre">Press center</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu">
                <ul class="footer__list">
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/contact-us">Contact us</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="https://biomedcentral.typeform.com/to/VLXboo">Leave feedback</a>
                        
                    </li>
                    
                    <li class="footer__item">
                        <a class="footer__link" href="//www.biomedcentral.com/about/jobs">Careers</a>
                        
                    </li>
                    
                </ul>
            </div>
            
            <div class="footer__menu footer__menu--follow">
                <div class="footer__follow">
                    <h3 class="footer__follow-title">Follow BioMed Central</h3>
                    <ul class="follow follow--inline">
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--twitter" href="https://twitter.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Twitter">
                                <span class="follow__label">Twitter</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--facebook" href="https://www.facebook.com/BioMedCentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Facebook">
                                <span class="follow__label">Facebook</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--gplus" href="https://plus.google.com/106226337984152901734/" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Google Plus">
                                <span class="follow__label">Google Plus</span>
                            </a>
                        </li>
                    
                        <li class="footer__follow-item follow__item">
                            <a class="follow__link follow__link--weibo" href="http://www.weibo.com/biomedcentral" target="_blank" data-track-event="click" data-event-category="Social Media" data-event-action="Click Follow Social Media" data-event-label="Weibo">
                                <span class="follow__label">Weibo</span>
                            </a>
                        </li>
                    
                    </ul>
                </div>
            </div>
        </div>
    </nav>


            </div>
        </div>
        <div class="branding-bar">
            <div class="logo branding-bar__logo">
                <img srcset="/static/images/logo-springernature-4230d19d5c.svg" src="/static/images/logo-springernature-828f4f84c8.png" class="logo__img branding-bar-logo__img" alt="Springer Nature Logo" />
            </div>
            <p class="branding-bar__copyright">&#169; 2017 BioMed Central Ltd unless otherwise stated. Part of <a class="branding-bar__link" href="http://www.springernature.com">Springer Nature</a>.</p>
        </div>
    </footer>
    <noscript class="js-cookie-banner-noscript">
        <div class="cookie-banner js-cookie-banner">
            <div class="cookie-banner__inner">
                <p class="cookie-banner__message">
                    We use cookies to improve your experience with our site.
                    <a href="https://www.biomedcentral.com/cookies"
                       class="cookie-banner__link"
                       data-track-event="click"
                       data-event-category="EU Cookie Law Banner"
                       data-event-action="Find out more">More information <span class="sr-only">about our cookie policy</span>
                    </a>
                </p>
                <button hidden class="cookie-banner__dismiss js-cookie-banner-dismiss"
                        data-track-event="click"
                        data-event-category="EU Cookie Law Banner"
                        data-event-action="Close"><span class="cookie-banner__dismiss-text">Close</span>
                </button>
            </div>
        </div>
</noscript>


    </div>
    
    <img class='tracker' style='display:none' src='/track/article/10.1186/1756-8722-5-5' alt=""/>

    <div id="JFulltext"></div>

    
    <script type="text/javascript" src="//cdn.pbgrd.com/bmc.js" async="async"></script>

    

    
<script>
(function() {
    var linkEl = document.querySelector('.js-ctm');
    if (linkEl && window.matchMedia && window.matchMedia(linkEl.media)) {
        var vendorScript = document.createElement('script');
        vendorScript.src = '/static/js/oscar-vendor-67103b4f35.js';
        vendorScript.async = false;
        document.body.appendChild(vendorScript);
        var appScript = document.createElement('script');
        appScript.src = '/static/js/oscar-app-4e91ea0ef9.js';
        appScript.async = false;
        document.body.appendChild(appScript);
    }
})();
</script>



<script type="text/javascript">
    if (config) {
        (function (d) {
            Array.prototype.forEach.call(d.getElementsByClassName('RealMediaAd'), function (adElement) {
                var iframe = d.createElement('iframe');
                iframe.frameBorder = '0';
                iframe.scrolling = 'no';
                var position = adElement.getAttribute("data-position"),
                        iframeInDoc = adElement.getElementsByClassName('Ad_content')[0].appendChild(iframe),
                        doc = iframeInDoc.contentWindow.document;

                doc.open().write('<body onload="window.location.href = '
                        + '\'/placeholder/v1/advertising/realMedia?siteWithPath=' + encodeURIComponent(config.siteWithPath)
                        + '&placement=' + position + '\';">');
                doc.close();
            });
        })(document);
    }
</script>



    
        <script type="text/javascript">
            document.addEventListener('readystatechange', function () {
                if (document.readyState === 'complete') {
                    setTimeout(function () {
                        var script = document.createElement("script");
                        script.type = "text/javascript";
                        script.src = "https://recommendations.springernature.com/latest/entry-point.js";
                        document.getElementsByTagName("head")[0].appendChild(script);
                    }, 0);
                }
            });
        </script>
    


    <script type="text/javascript">
        var _kiq = _kiq || [];
        (function () {
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/9CC.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
            setTimeout(function () {
                var d = document, f = d.getElementsByTagName('script')[0], s = d.createElement('script');
                s.type = 'text/javascript';
                s.async = true;
                s.src = '//s3.amazonaws.com/ki.js/47412/aC6.js';
                f.parentNode.insertBefore(s, f);
            }, 1);
        })();
    </script>


<noscript>
	<img hidden src="https://verify.nature.com/verify/nature.png" border="0" width="0" height="0" style="display: none">
</noscript>
</body>
</html>

